Synapsin I/II double knockout mice and spontaneously hypertensive rats : two animal models with implications for neurological disorders by Grabovac, Saha
                                                                                                                                    
 
 THESIS FOR THE DEGREE CANDIDATA PHARMACIAE 
 
 
SYNAPSIN I/II DOUBLE KNOCKOUT MICE  
AND  
SPONTANEOUSLY HYPERTENSIVE RATS; 
 
 TWO ANIMAL MODELS WITH IMPLICATIONS  
FOR NEUROLOGICAL DISORDERS 
 
 
 
by 
 
ŠAHA GRABOVAC 
 
 
 
Department of Biochemistry 
Institute of Basic Medical Sciences, 
Faculty of Medicine 
and 
Department of Pharmaceutical Biosciences 
School of Pharmacy 
Faculty of Mathematics and Natural Sciences 
University of Oslo 
November 2006 
 
 1
ACKNOWLEDGMENTS 
This investigation was carried out at the Department of Biochemistry, Institute of Basic 
Medical Sciences, University of Oslo in the period November 2005 to November 2006, 
leading to the degree Candida Pharmaciae. 
 
I would like to express my gratitude to the leaders of our group, and my supervisors at the 
Department of Biochemistry, Professor Frode Fonnum and Professor Ivar Walaas for 
taking the chance of hiring me in the first place and for encouraging me to pursue further 
studies. I am also thankful to them and to Ph.D. student Kristin Huse Haug for spending 
time they didn’t have critically reading my manuscript and providing useful comments in 
the writing process. In addition I would like to thank my supervisor at the School of 
Pharmacy, University of Oslo, Professor Hege Christensen for providing good help before 
the pharmacology exam this spring.  
 
I would like to thank all the present members of our group for providing an excellent work 
environment, you make the Department of Biochemistry a great place to be! 
 
But first and foremost, I wish to thank Ph.D. student Inger Lise Bogen with all my heart. I 
greatly appreciate her exceptional scientific knowledge and dedication. Her help was 
INVALUABLE both in the experimental as well as in the theoretical approach. I consider 
myself very lucky to be able to work with her on this project. Thank U for putting so much 
effort in me ☺ ! 
 
Finally I wish to thank my parents, Asim and Ramiza, my brothers Adnan and Asmir, and 
my friends for always being there for me and for always supporting my choices in life. One 
special acknowledgement goes to Alem Jašarević, my dear boyfriend. Your love, support 
and patience is what keeps me going. Thank you for being as amazing as only you can be!  
 
Oslo, November 2006 
_____________________ 
Saha Grabovac 
 2
CONTENTS  
ACKNOWLEDGMENTS........................................................................................ 1 
CONTENTS .............................................................................................................. 2 
SUMMARY ............................................................................................................... 6 
ABBREVIATIONS................................................................................................... 8 
1. INTRODUCTION .............................................................................................. 10 
1.1 THE NERVOUS SYSTEM ..................................................................................10 
1.1.1 SYNAPTIC TRANSMISSION ......................................................................10 
1.1.2 THE SYNAPTIC VESICLE CYCLE ...................................................................................... 11 
1.2 NEUROTRANSMITTERS ........................................................................................14 
1.2.1 Γ  - AMINOBUTYRIC ACID .........................................................................14 
1.2.2 GLUTAMATE ......................................................................................................................... 16 
1.2.3 ACETYLCHOLINE...................................................................................................................... 16 
1.2.4 DOPAMINE.................................................................................................................................. 18 
1.3  NEUROTRANSMITTER TRANSPORTERS ..........................................................19 
1.3.1 PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORTERS ............................... 19 
1.3.2 VESICULAR NEUROTRANSMITTER TRANSPORTERS ................................................. 19 
VESICULAR GABA TRANSPORTER..................................................................................................... 20 
VESICULAR GLUTAMATE TRANSPORTER........................................................................................ 21 
VESICULAR ACETYLCHOLINE TRANSPORTER................................................................................ 21 
1.4 NEUROTRANSMITTER RECEPTORS .............................................................22 
1.4.1 DOPAMINE RECEPTORS.......................................................................................................... 22 
1.4.2 N-METHYL-D-ASPARTATE RECEPTOR ................................................................................ 23 
1.5 THE SYNAPSINS................................................................................................24 
1.5.1 PRIMARY STRUCTURE AND PHYSIOCHEMICAL PROPERTIES OF THE SYNAPSINS25 
1.5.2. THE FUNCTION OF THE SYNAPSINS .................................................................................. 26 
1.6 ANIMAL MODELS ...................................................................................................26 
1.6.1 GENE KNOCKOUT TECHNOLOGY ......................................................................................... 26 
1.6.2 THE SPONTANEOUSLY HYPERTENSIVE RAT .................................................................... 27 
1.7 AIMS OF THE STUDY........................................................................................28 
2. MATERIALS AND METHODS....................................................................... 29 
2.1 MATERIALS..............................................................................................................29 
 3
2.2 ANIMALS ..................................................................................................................29 
2.2.1 SYNAPSIN I/II DOUBLE KNOCKOUT MICE.......................................................................... 29 
2.2.2 SPONTANEOUS HYPERTENSIVE RATS ................................................................................ 29 
2.3 SAMPLE PREPARATION ........................................................................................30 
2.3.1 PREPARATION OF CRUDE HOMOGENATE FROM RATS DEVOID OF    SYNAPSIN I 
AND II.................................................................................................................................................... 30 
2.3.2 PREPARATION OF CRUDE HOMOGENATE FROM WKY AND SHR RATS ..................... 30 
2.3.3 PREPARATIONS OF HOMOGENATE FROM DIAPHRAGM AND TONGUE .................... 30 
PROCEDURE 1...................................................................................................................................... 30 
PROCEDURE 2...................................................................................................................................... 31 
PROCEDURE 3...................................................................................................................................... 31 
PROCEDURE 4...................................................................................................................................... 31 
PROCEDURE 5...................................................................................................................................... 32 
2.4 PROTEIN DETERMINATION..................................................................................32 
2.5 WESTERN BLOTTING.............................................................................................32 
2.5.1 GEL PREPARATION .................................................................................................................. 33 
2.5.2 GEL ELECTROPHORESIS ........................................................................................................ 33 
2.5.3 MEMBRANE TRANSFER .......................................................................................................... 34 
2.5.4 BLOCKING NON SPECIFIC BINDING ................................................................................... 35 
2.5.5 ADDITION OF THE PRIMARY AND SECONDARY ANTIBODY ......................................... 35 
2.5.6 DETECTION ................................................................................................................................ 35 
2.6 RECEPTOR BINDING ASSAY ................................................................................36 
2.6.1 FUNDAMENTALS OF RECEPTOR BINDING ASSAY........................................................... 36 
2.6.2 DEFINITION OF SPECIFIC BINDING ................................................................................... 37 
TOTAL BINDING................................................................................................................................... 37 
NONSPECIFIC BINDING...................................................................................................................... 37 
SPECIFIC BINDING.............................................................................................................................. 37 
2.6.3 TISSUE PREPARATION ............................................................................................................ 37 
2.6.4 LIGANDS AND THE EXPERIMENTAL CONDITIONS FOR RECEPTOR BINDING ASSAY
................................................................................................................................................................ 38 
TEST 1:................................................................................................................................................... 39 
TEST 2:................................................................................................................................................... 39 
2.6.5 RECEPTOR BINDING ASSAY ................................................................................................... 39 
2.7 STATISTICS ..............................................................................................................39 
3. RESULTS ............................................................................................................ 40 
3.1 THE LEVEL OF VESICULAR PROTEINS IN THREE BRAIN REGIONS OF 
SYNAPSIN I/II DKO MICE.............................................................................................40 
3.1.1 VESICULAR ACETYLCHOLINE TRANSPORTER............................................................ 40 
3.1.2 VESICULAR GLUTAMATE TRANSPORTER..................................................................... 41 
 4
3.1.3 VESICULAR GABA TRANSPORTER .................................................................................. 42 
3.1.4 SYNAPTOPHYSIN ................................................................................................................. 43 
3.1.5 GLUTAMIC ACID DECARBOXYLASE ............................................................................... 43 
3.1.6 THE LEVELS OF CHOLINERGIC VESICLES IN PHERIPHERAL NEURONS IN 
SYNAPSIN I/II DKO............................................................................................................................. 44 
3.2 RELATIVE LEVELS OF DIFFERENT VESICULAR PROTEINS IN 
NEOSTRIATUM, CORTEX AND PONS MEDULLA COMPARED TO LEVELS IN 
THE CEREBRUM............................................................................................................47 
3.3 STUDIES ON THE DOPAMINERGIC SYSTEM IN AN ANIMAL ..................48 
MODEL FOR ADHD .......................................................................................................48 
3.3.1 D1/D5 RECEPTOR BINDING IN SHR.................................................................................. 48 
3.3.1.1 Method testing............................................................................................................................ 49 
TEST 1:................................................................................................................................................... 49 
TEST 2 :.................................................................................................................................................. 49 
3.3.2 DOPAMINE D1- LIKE RECEPTOR IN CEREBRUM AND STRIATUM ........................... 50 
3.3.3 CALCYON, COMT AND NMDA-RECEPTOR SUBUNITS................................................. 51 
4. DISCUSSION...................................................................................................... 55 
4.1 THE LEVEL OF VESICULAR PROTEINS IN SYNAPSIN I/II DOUBLE 
KNOCKOUT MICE .........................................................................................................55 
4.1.1 THE LEVELS OF VESICULAR TRANSPORTERS IN SYNAPSIN I/II DOUBLE 
KNOCKOUT MICE IN CENTRAL NERVOUS SYSTEM .................................................................. 55 
4.1.2 THE LEVELS OF CHOLINERGIC VESICLES IN PERIPHERAL NEURONS IN SYNAPSIN 
I/II DKO ................................................................................................................................................. 57 
4.1.3 DIFFERENCE IN THE DEPENDENCE OF SYNAPSIN I AND II FOR SPECIFIC 
VESICULAR TRANSPORTERS .......................................................................................................... 57 
4.1.3 PROTEINS IN WILD-TYPE MICE IN THREE BRAIN SECTIONS COMPARED TO 
CEREBRUM.......................................................................................................................................... 58 
4.2 STUDIES ON THE DOPAMINERGIC SYSTEM IN AN ANIMAL ..................59 
MODEL FOR ADHD .......................................................................................................59 
4.2.1 THE D1-LIKE  RECEPTOR BINDING IN SHR COMPARED TO WKY................................. 60 
4.2.2 CALCYON AND COMT............................................................................................................... 61 
4.2.3 NMDA-RECEPTORS................................................................................................................... 62 
4.3 CONCLUSION ....................................................................................................63 
REFERENCES........................................................................................................ 65 
APPENDIX.............................................................................................................. 70 
I. CHEMICALS AND REAGENTS.................................................................................70 
 5
II. CONTENT OF BUFFERS AND SOLUTIONS...........................................................72 
a)  BUFFERS AND SOLUTIONS FOR WESTERN BLOTTING............................................................ 72 
b) BUFFERS AND SOLUTIONS FOR RECEPTOR BINDING ASSAY ................................................. 73 
c) SOLUTIONS FOR PREPARATION OF DIAPHRAGM AND TONGUE ........................................... 74 
 
  
 
 
 
 
 
 
 
 
 
 
 
 6
SUMMARY 
 
The synapsins are abundant phosphoproteins associated with synaptic vesicles. Although 
synapsins were among the first vesicle proteins discovered, their functions still remain 
incompletely understood. Previous studies have reported major decreases in the number of 
synaptic vesicles in synapsin deficient brains, but knowledge about  which classes of 
vesicles are affected has been lacking. In the first part of this study, the consequences of the 
deletion of synapsin I and II for different subgroups of vesicles were studied in different 
brain regions. 
 
It was recently reported by our group that the levels of VGLUT1, VGLUT2 and VGAT are 
decreased by approximately 40% in mice devoid of synapsin I and II. In this study, the 
main focus was on the effects on cholinergic vesicles, using VAChT as a cholinergic 
marker, in mice lacking synapsin I and II. The levels of different vesicular transporters 
were studied in three brain areas, the neostriatum, cortex and pons medulla. The levels of 
VGLUT-1, VGLUT-2 and VGAT were decreased by 30-50% in all the brain areas 
examined. In contrast, the levels of VAChT were decreased by only 23% in the 
neostriatum, and were present at the same levels as wild-type in cortex and pons medulla. 
We do not know whether the cholinergic terminals in striatum, cortex and pons medulla, 
differ regarding their dependence and co/localization with synapsins. Synaptic vesicles are 
covered with synapsins and could serve some role of vesicle stabilization. A decrease in 
synaptic vesicles in mice lacking synapsins could indicate that synapsins serve a role in 
vesicle stabilization. Lack of synapsins could therefore induce the vesicles to undergo 
spontaneous degradation..  
 
In the second part of the study, the aim was to measure the amounts of proteins involved in 
the dopaminergic system in an animal model for the “attention deficity hyperactivity 
disorder” (ADHD). The spontaneous hypertensive rat (SHR) is the only animal model that 
has been found to demonstrate all the behavioural characteristics of ADHD, namely 
hyperactivity, impulsivity and problems with sustained attention. Since abnormal 
dopaminergic responses appear as one of main markers for ADHD, the amount of 
dopamine D1–like receptors was measured. Our results show an increase by 21% in the 
density of D1-like receptors in cerebrum. This increase in the amounts of D1-like receptors 
could be a compensatory mechanism for dopamine hypofunction (evt reduced dopamine 
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release) in SHR, and confirms the hypothesis of a dysregulation of the dopaminergic 
system in ADHD. No difference was found in the levels of the D1-interacting protein, 
calcyon, or the enzyme which catalyzes the degradation of dopamine, COMT. Since many 
dopaminergic effects are mediated through interaction with glutamatergic 
neurotransmission, the levels of the NMDA-subunits of the NMDA-receptor were 
examined in neostriatum and cerebrum. No changes were detected on the protein level of 
NMDA-1 and NMDA-2A/B, but one cannot exclude their involvement in the aetiology of 
ADHD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 8
ABBREVIATIONS 
aa      Amino acid 
ACh      Acetylcholine 
AChE                  Acetylcholinesterase 
ADHD                “ Attention-deficit hyperactivity disorder” 
APS                     Ammonium persulfate 
BCA                    Bicinchoninic acid 
BSA                     Bovine Serum Albumine 
CaM                    Ca2+/calmodulin dependent protein kinase I 
cAMP                  cyclic Adenosine Mono Phosphat 
ChAT                  Choline Acetyltransferase 
CNS                    Central Nervous System 
DKO                    Double Knockout 
ES cells                embryonic stem cells 
GABA       γ-aminobutyric acid 
GAD       glutamic acid decarboxylase 
HRP                     Horseradish Peroxidase 
5-HT       Seretonin 
kDa       kilo Dalton  
KO       Knockout 
NMDA      N-methyl-D-aspartate 
PKA                     Protein Kinase A 
PNS                      Periferal Nervous System 
rpm                       revolutions per minute 
SDS                      Sodium Dodecyl Sulphat 
SDS-PAGE          Sodium Dodecyl Sulphate-Polyacrylamide Gel 
SHR        Spontaneuosly hypertensive rat 
TBS                      Tween- Tris-buffered salt solution with tween 20 
TEMED                N,N,N′,N′-Tetramethylethylenediamine 
VAMP                   vesicle-associated  membrane protein 
VGLUT               vesicular glutamate transporter 
VGAT                  vesicular GABA transporte 
VAChT                vesicular acetylcholine transporter 
VMAT                 vesicular monoamine transporter 
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w/v                       weight/volume 
WKY                   Wistar-Kyoto  
WT       Wild Type 
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1. INTRODUCTION 
 
1.1 THE NERVOUS SYSTEM 
The brain is composed of glia cells and neurons. Every neuron is divided in four 
structurally different unities:  a cell body, dendrittes, axon and thousands of nerveterminals. 
A single neuron can be connected to many other neurons and the total number of neurons 
and connections in a network can be extremely large. Connections, called synapses, are 
usually formed from axon neuroterminals to dendrittes. 
 
1.1.1 SYNAPTIC TRANSMISSION 
The connections between neurons are abundant in the brain. These connections, better 
known as synapses, branch into three groups regarding their physiological typing, namely 
excitatory, inhibitory and modulatory. Regarding the synaptic type, there is a chemical 
synapse which enable cell-to-cell communication via secretion of neurotransmitters, or less 
common, an electrical synapse, where signals are transmitted through gap junction (Cohen-
Cory, 2002; Siegel G.J. et al., 1999). 
 
 
Figure 1.1 An illustration of synaptic transmission 
 
Chemical neurotransmission is the major means by which nerves communicate with one 
another in the nervous system. Synaptic transmission is initiated when an action potential 
triggers neurotransmitter release from a presynaptic nerve terminal, as shown in figure 1.1 
(Sudhof, 2004). Stimuli caused by an action potential, opens voltage-gated Ca2+ channels, 
triggering exocytose of neurotransmitters from synaptic vesicles. Released 
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neurotransmitters interact with receptors in the postsynaptic membrane, thereby activating 
it. Released neurotransmitters are inactivated either by reuptake into the nerve terminal by 
neurotransmitter re-uptake pump, by degradation or by uptake and metabolism by glial 
cells (Masson et al., 1999). 
 
1.1.2 THE SYNAPTIC VESICLE CYCLE 
The presynaptic nerve terminal is filled with small translucent synaptic vesicles. These 
organelles are abundant, and are approximately ~20 nm in radius (Sudhof, 2004).The major 
function of synaptic vesicles is to take up and store neurotransmitters, and to fuse and bud 
from membranes.  
  
 
Figure 1.2 The synaptic vesicle cycle: Synaptic vesicles are filled with neurotransmitters by active transport 
(step 1) and form the vesicle cluster that may represent the reserve pool (step 2). Filled vesicles dock at the 
active zone (step 3), where they undergo a priming reaction (step 4) that makes them competent for Ca2+ 
triggered fusion-pore opening (step 5). After fusion-pore opening, synaptic vesicles undergo endocytosis and 
recycle via several routes: local reuse (step 6), fast recycling without an endosomal intermediate (step 7), or 
clathrin-mediated endocytosis (step 8) with recycling via endosomes  (step 9). The steps in exocytosis are 
indicated by red arrows and the steps in endocytosis and recycling are indicated by yellow arrows (Sudhof, 
2004). 
 
 
The key event in the synaptic vesicle cycle is exocytosis by membrane fusion. For this to 
happen, several steps occur both before and after exocytosis. The synaptic vesicle cycle can 
be divided into 9 steps , as depicted in figure 1.2 (Sudhof, 1995; Sudhof, 2004) 
1) NEUROTRANSMITTER UPTAKE:  Neurotransmitters are taken up in synaptic vesicles 
driven by an electrochemical gradient created by a proton pump. 
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2) CLUSTERING AT THE ACTIVE ZONE: Synaptic vesicles cluster in front of the active 
zone. 
3) DOCKING: Synaptic vesicles filled with neurotransmitters attach to the active zone 
of the presynaptic membrane. 
4) PRIMING: After docking, synaptic vesicles go through a maturation process that 
makes them competent for fast Ca2+ triggered membrane fusion. 
5) FUSION/EXOCYTOSIS: Primed synaptic vesicles are stimulated for rapid 
fusion/exocytosis by a Ca2+ spike during an action potential. Neurotransmitters are 
released in less than 1 msec. 
 
After fusion-pore opening, synaptic vesicles endocytose and recycle probably by three 
alternative pathways, “kiss and stay”, “kiss and run” or budding from an endosomal 
intermediate: 
 
6) “KISS AND STAY”:  Vesicles are reacidified and refilled with neurotransmitters 
without undocking, thus remaining in the readily releasable pool. 
7) “KISS AND RUN”:   Vesicles undock and recycle locally to reacidify and refill with 
neurotransmitter (back to step 1 and 2). 
8) VESICLE ENDOCYTOSIS VIA CLATHRIN COATED PITS: Synaptic vesicles endocytose 
via clathrin coated pits and reacidify and refill with neurotransmitters directly. 
9) RECYCLING VIA ENDOSOMES:  Synaptic vesicles pass through an endosomal       
intermediate, and refill with neurotransmitters. 
 
The synaptic vesicle cycle is unique in its speed and its tight regulation, due to the fact that 
one cycle takes approximately 60 sec to be finished (Siegel George J. et al., 1999). 
 
Several proteins of synaptic vesicles have been identified, dividing them into transport 
proteins, membrane proteins, and proteins involved in neurotransmitter release. Transport 
proteins are proteins involved in the uptake of neurotransmitters. Trafficking proteins are 
both membrane proteins and proteins involved in neurotransmitter release. They mediate 
membrane traffic of the vesicles, such as docking, fusion and budding (Sudhof, 1995; 
Sudhof, 2004). The structure of trafficking proteins discovered so far is shown in figure 
1.3.  
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Figure 1.3 The structure of major trafficking proteins of synaptic vesicles that have been molecularly 
characterized (Sudhof, 2004) 
 
Two trafficking proteins were examined in this investigation, namely synaptophysin and 
synapsins. Since the synapsins are described in detail in section 1.5, the main focus here is 
on synaptophysin. Synaptophysin  is a membrane glycoprotein of synaptic vesicles that is 
ubiquitously expressed in all neurons and in many endocrine cells, accounting for 6–8% of 
the total synaptic vesicle proteins (Jahn et al., 1985). It is currently the most widely used 
marker for nerve terminals. Synaptophysin 1 has four transmembrane domains with both 
N- and C-terminus facing the cytoplasm, as shown in figure 1 (Jahn et al., 1985). Based on 
the predicated structure, it was suggested that synaptophysin forms a channel in the 
synaptic vesicle membrane and acts as the major Ca2+-binding protein in synaptic vesicles 
(Gincel and Shoshan-Barmatz, 2002). Indeed, it has been demonstrated that upon 
reconstitution into a planar lipid bilayer, purified synaptophysin displayed voltage-sensitive 
channel activity (Gincel and Shoshan-Barmatz, 2002). The function of synaptophysin is, 
however, as yet unknown (Sudhof, 2004). On the one hand, its location in the synaptic 
vesicle membrane and its interaction with vesicle-associated  membrane protein, VAMP 
(also known as synaptobrevin), implicated in synaptic vesicle docking and fusion, suggests 
its involvement in exocytosis (Gincel and Shoshan-Barmatz, 2002). However, the function 
of  synaptophysin in neurotransmitter release has been questioned because mutant mice 
lacking synaptophysin  displayed normal synaptic transmission (Gincel and Shoshan-
Barmatz, 2002). As typical for synaptic vesicle proteins, synaptophysin  represents a small 
protein family with three members, synaptophysin 1,  synaptoporin (synaptophysin 2) and 
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panthophysin (Leube, 1994). Like synaptophysin 1, synaptoporin is widely expressed in 
neurons and colocalizes with synaptophysin 1 on synaptic vesicle whereas panthophysin is 
expressed in all tissues (Leube, 1994).  
 
1.2 NEUROTRANSMITTERS  
Neurotransmitters are released from synaptic vesicles when Ca2+ influx through voltage-
gated channels. This release of neurotransmitters can be enhanced either by increasing the 
number of active synaptic vesicles, or by increasing the probability for the single docked 
vesicle to fuse (Sudhof and Jahn, 1991). The neurotransmitters of interest in this study are 
discussed in chapter 1.2.1 – 1.2.4.  
 
1.2.1 γ  - AMINOBUTYRIC ACID 
γ-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian 
brain and serves signalling and trophic functions in several neuronal tissues (Masson et al., 
1999). The rate-limiting step in the synthesis of GABA is the decarboxylation of glutamate, 
a reaction catalyzed by the enzyme glutamic acid decarboxylase (GAD) (Bu et al., 1992). 
GABA taken up into nerve terminals can be reutilized, while GABA taken up in glia is 
metabolized to succinic semialdehyde by GABA transaminase. and cannot be resynthesized 
to GABA since glia cells lack GAD (Siegel George J. et al., 1999). 
 
High levels of GABA are found within the neocortex, hippocampus, cerebellum, septal 
nuclei and the reticular nucleus of the thalamus (McIntire et al., 1997).  
 
A growing body of evidence suggests a role for altered GABAergic function in 
neurological and psychiatric disorders of humans, including Huntington’s desease, 
epilepsy, tardive dyskinesia, alcoholism, schizophrenia, sleep disorders, Parkinson’s 
disease and mental retardation (Siegel George J. et al., 1999). This is the reason why 
GABAergic transmission is an important therapeutic target. 
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Figure 1.4 The molecular structure of GABA 
 
Since GAD65 was examined in this investigation, a brief description of GAD isoforms will 
be presented here. GAD exists as two major isoforms, called GAD65 and GAD67, which 
are the products of two independently regulated genes located on chromosomes 2 and 10, 
respectively, in humans (Bu et al., 1992). The N-terminal domain (with 23% identity 
between the two human GADs, as depicted in figure 1.5) is involved in subcellular 
targeting, membrane association and heteromeric interactions. The C-terminal is much 
larger and more conserved (73% identity, as depicted in figure 1.5), having a domain that 
contains the catalytic centre (Soghomonian and Martin, 1998). Membrane association of 
GAD65 involves phosphorylation of the N-terminal domain and other interactions 
(Soghomonian and Martin, 1998). Membrane association of GAD67 appears to be 
secondary to that of GAD65 and involves the formation of GAD65–GAD67 heteromers 
through undefined interactions between the N-terminal domains of the two forms (Kanaani 
et al., 1999). These differences in membrane interactions might account for the differences 
in subcellular localization of the two GAD forms in the brain, and they could be involved 
in the biosynthesis of GABA in different intracellular compartmnts (Soghomonian and 
Martin, 1998). Although both isoforms synthesize the neurotransmitter GABA, GAD67 
might preferentially synthesize cytoplasmic GABA and  
GAD65 might preferentially synthesize GABA for vesicular release. 
 
Figure 1.5Comparison of glutamate decarboxylase 65 (GAD65) 
and GAD67 proteins. The N-terminal 
domain is on the left side.. Phosphorylation of four serines near 
the N-terminus of GAD65 appears to be involved in membrane 
association. The catalytic domain of the two GAD proteins is 
more highly conserved (73% sequence identity). It contains six 
motifs that are structurally conserved in the GADs and related 
pyridoxal-phosphate-dependent enzymes and also several 
conserved residues that interact directly with the cofactor 
(Soghomonian and Martin, 1998). 
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1.2.2 GLUTAMATE 
The amino acid glutamic acid, also referred to as glutamate, is the major excitatory 
neurotransmitter, found in large amounts in the central nervous system (CNS). It is 
synthesised in neuronal tissues either by transamination of α-ketoglutarate or from 
glutamine by the action of glutaminase. Glutamate mediates through the interaction with a 
large, and still growing number of receptors, both ionotropic and metabotropic, fast 
excitatory neurotransmission as well as synaptic plasticity. Since glutamate does not cross 
the blood-brain barrier, it is stored within nerve terminals in virtually every neuron in the 
CNS. When taken up into glial cells, glutamate is converted into glutamine (Siegel George 
J. et al., 1999).  
 
Elevated levels of glutamate can induce severe damages to target neurons due to its 
characteristic as being a potent exitotoxin. It’s removal from the synaptic cleft is of key 
importance to maintain the integrity of neuronal tissue (Masson et al., 1999). Since 
elevated levels of glutamate has been implicated in epilepsy, ischemic brain damage and 
learning (Siegel George J. et al., 1999), glutamatergic pathways are of great therapeutic 
interest. 
 
 
 
Figure 1.6 The molecular structure of glutamate 
 
 
1.2.3 ACETYLCHOLINE  
Acetylcholine is one of the major modulator of brain functions. The synthesis of 
acetylcholine is a single step reaction catalyzed by the enzyme choline acetyltransferase 
(ChAT) using acetyl coenzyme A and choline taken up by the high affinity Na+-dependent 
choline transporter (Prado et al., 2002). Acetylcholine is metabilised by cholinesterases, 
acetylcholinesterase (AChE) or butyrylcholinesterase (Siegel George J. et al., 1999) 
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Figure 1.7 The molecular structure of acetylcholine 
 
As shown in figure 1.8 of central cholinergic pathways in rat brain, forebrain projections 
are classified into six main central pathways (Ch1–Ch6), linked to the origin of the nuclei 
where the cholinergic fibres arise. Cholinergic nuclei from the septum (Ch1) and the 
vertical limb of the diagonal band (Ch2) project only on the hippocampus whereas 
pedunculopontinus nucleus (part of Ch5) and laterodorsal tegmental nucleus (Ch6) from 
the brainstem project on the thalamus. Cholinergic nuclei from the lateral part of the 
horizontal limb of the diagonal band (Ch3) project to the olfactory bulb. The pathway 
innervating the cortex (Ch4) mainly originates from the nucleus basalis magnocellular. The 
only difference between cholinergic projecetions in human brain compared to rat brain is 
that in the rat, Ch4 pathway groups originate from several other nuclei in addition to the 
nucleus basalis magnocellular, such as the substantia innominata, diagonal band 
nuclnucleus ansa lenticularis and a part of the magnocellular preoptic nucleus (Lucas-
Meunier et al., 2003). In contrast, the neostriatal regions in the basal ganglia 
(caudatoputamen, nucleus accumbens and olfactory tubercle) contain local cholinergic 
interneurons only. 
 
 
Figure 1.8 Rat central 
cholinergic pathways 
(Lucas-Meunier et al., 
2003).  
 
 
 
 
 
 
Acetylcholine acts as a neurotransmitter in the peripheral nervous system (PNS) as well. 
Muscarinic receptors are found in visceral smooth muscle, in cardiac muscle, in secretory 
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glands and in the endothelial cells of the vasculature. Except for endothelial cells, each of 
these sites receives cholinergic innervation. The responses can be excitatory or inhibitory, 
depending on the tissue (Siegel George J. et al., 1999). 
 
Modulation of acetylcholine release is crucial for the function of the nervous system. 
Dysfunction of cholinergic transmission has been linked to a number of pathological 
conditions (Prado et al., 2002), such as Alzheimer’s disease, Parkinson’s disease, 
Creutzfeldt-Jakob disease, Down syndrome, Korsakoff’s syndrome. (Lucas-Meunier et al., 
2003). 
 
1.2.4 DOPAMINE 
Dopamine is the major catecholamine in the CNS (Jaber et al., 1996), and it has been 
shown that the dopaminergic system mediates control of movements, hormone secretion, 
cognitive, emotional and reward behaviours (Brusa, 1999). 
 
Dopamine is synthesized by the hydration of the amino acid tyrosine to DOPA by tyrosine 
hydroxylase, being the rate-limiting step. Thereafter DOPA is decarboxylated by aromatic-
L-amino-acid decarboxylase. The catechol-O-Methyltransferase (COMT) and monoamine 
oxidase (MAO), catalyses degradation of catecholamines (Siegel George J. et al., 1999). 
 
 
Figure 1.9 The molecular structure of dopamine  
 
The dopaminergic system consists of three major pathways. The nigro-striatal branch 
originate in the substantia nigra and project mainly to the neostriatum (the caudate-putamen 
complex). Nearly 80% of all dopamine is found in neostriatum. The meso-cortico and the 
meso-limbic branch originate in the ventral tegmental area and project to the prefrontal 
cortex, the nucleus accumbens septi and the olfactory tubercle (Siegel George J. et al., 
1999). 
 
The dopaminergic system has been thoroughly studied, mainly because alterations in 
dopamine neurotransmission are involved, directly or indirectly, in several brain 
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dysfunctions, e.g. schizophrenia, Parkinson’s disease, Attention-deficit hyperactivity 
disorder (ADHD), Huntington’s disease, Tourettes syndrome and in drug addiction 
(Castellanos and Tannock, 2002; Jaber et al., 1996). 
 
1.3  NEUROTRANSMITTER TRANSPORTERS 
Neurotransmitter transporters can be classified according to their primary structure and site 
of action. According to this criterion two families of neurotransmitter transporters have 
been classified, namely plasma membrane transporters and vesicular membrane 
transporters (Masson et al., 1999). Vesicular neurotransmitter transporters are described in 
greater detail then plasma membrane neurotransmitter transporters, since vesicular 
transporters are of great interest in this study. 
 
1.3.1 PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORTERS 
Plasmamembrane transporters are responsible for neurotransmitter uptake at the plasma 
membrane, where all transporters are dependent on the Na+ gradient for their activity. 
Depending on whether they need Cl- or K+ in addition to be active, these transporters can 
further be classified as Na+/Cl--dependent or Na+/K+-dependent neurotransmitter 
transporters. The monoamine (dopamine, norepinephrine and serotonin) and inhibitory 
amino acid (e.g. GABA) transporters  are all Na+/Cl--dependent transporters, while 
excitatory glutamate and aspartate are Na+/K+-dependent transporters. There are differences 
in these two classes of transporters, amongst others in their pharmacological properties, 
regulatory properties, regional and cellular localizations and implications in 
neuropathologies (Masson et al., 1999). 
 
1.3.2 VESICULAR NEUROTRANSMITTER TRANSPORTERS 
At present, vesicular transporters for the monoamines (VMAT-1 and VMAT-2), 
acetylcholine (VAChT), GABA (VGAT) and glutamate (VGLUT-1, VGLUT-2 and 
VGLUT-3) have been described (Fykse and Fonnum 1988; Fykse and Fonnum 1996; 
Maycox et al., 1990). Synaptic vesicles accumulate and store neurotransmitters at high 
concentrations by active transport, driven by a vacuolar proton (H+) pump. This ATP-
driven H+-pump, energize neurotransmitter uptake by proton pumping which acidifies the 
organelle lumen, hereby generating a pH difference (∆pH), or in the absence of proton 
generates a large membrane potential (∆Ψ) (Maycox, Hell, and Jahn, 1990). Synaptic 
vesicles express specific and distinct neurotransmitter transporters which define transmitter 
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specificity and amount of transmitter in the vesicles (Sudhof and Jahn, 1991).These 
proteins are all ATP-dependent, and sequence analyses have predicted a structure with 10-
12 membrane-spanning domains. However, the driving force behind the vesicular transport 
of amino acid transmitters differs from the transport of monoamines and ACh. While 
VMATs and VAChT chiefly rely on the pH gradient (ΔpH) across the vesicle membrane to 
drive active transport of neurotransmitter into the vesicle, vesicular glutamate transport 
depends primarily on the electrical gradient and vesicular GABA transport depends more 
equally on both ΔpH and Δψ . 
 
 
Figure 1.10: The structure of vesicular neurotransmitter transporters of synaptic vesicles are depicted 
schematically. For simplicity, different vesicular transporters are pictured in the same synaptic vesicle 
although they do not colocalize in situ. Based on (Gasnier, 2000; Masson et al., 1999; Maycox, Hell, and 
Jahn, 1990). 
 
VESICULAR GABA TRANSPORTER 
The vesicular GABA transporter (VGAT) is a protein with ten transmembrane domains, 
expressed in regions containing GABAergic neurons. It has a long NH2- and a short 
COOH-intracytoplasmic termini, as shown in figure 1.10. (McIntire et al., 1997; Sagne et 
al., 1997).  
 
VGAT is responsible for the uptake and storage of GABA by synaptic vesicles in the 
central nervous system, although it appears to be responsible also for the uptake of glycine 
(McIntire et al., 1997; Sagne et al., 1997). VGAT is different from the plasma membrane 
transporters in that it is driven by a proton electrochemical gradient across the vesicle 
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membrane. The substrate affinity for this transporter is low (Gasnier, 2000; Maycox, Hell, 
and Jahn, 1990). So far, only one isoform of VGAT is known. 
 
VESICULAR GLUTAMATE TRANSPORTER 
There are three known vesicular glutamate transporters (VGLUTs), namely VGLUT-1, 
VGLUT-2 and VGLUT-3 (Fremeau et al., 2004). VGLUT-1 have six transmembrane 
domains, while VGLUT2 and VGLUT3 have eight transmembrane domains, all with N-
and C-terminal regions facing the cytosol.VGLUT-1 and VGLUT-2 are both  necessary 
and sufficient for uptake and storage of glutamate and thus comprises the sole determinant 
for a glutamatergic phenotype. Both VGLUTs are different from the plasma membrane 
transporters in that they are driven by a proton electrochemical gradient across the vesicle 
membrane. VGLUT1 and VGLUT2 show complementary expression patterns. In contrast 
VGLUT 3 defines a new distinct glutamatergic system in brain which is strictly seperated 
from VGLUT 1 and VGLUT 2 synapses. Co-localization with the acetylcholine transporter 
VAChT and the monoamine transporter 2 VMaT 2 has been observed (Fremeau et al., 
2002; Gras et al., 2002). 
 
VESICULAR ACETYLCHOLINE TRANSPORTER 
Vesicular acetylcholine transporter (VAChT)  is a 12 transmembrane transporter, with N- 
and C-terminal regions directed to the cytosol, as depicted in figure 1.10 (Roghani et al., 
1994). VAChT is a selective marker of cholinergic neurons, localized in small, clear 
synaptic vesicles of axon terminals (Prado et al., 2002). This transporter catalyzes the 
exchange of 2 H+ per cationic transmitter, and chiefly relies on proton gradient (Gasnier, 
2000; Prado et al., 2002). 
 
Both VAChT and ChAT are encoded by two embedded genes, the VAChT gene lying 
within the first intron of the ChAT gene, being co-expressed. This unique organization was 
named “cholinergic gene locus”, and it has been shown that ChAT and VAChT proteins are 
co-expressed (Prado et al., 2002) 
 
In the PNS, VAChT was detected in motor endplates of skeletal muscles as well as in 
fibers of sympathetic and parasympathetic abdominal ganglia, heart atrium, respiratory 
tract, and salivary and lacrimal glands (Arvidsson et al., 1997), indicating that VAChT can 
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be used as a tool for the study of cholinergic neurons in the central and peripheral nervous 
systems. 
 
1.4 NEUROTRANSMITTER RECEPTORS 
Dopamine D1-like receptors and NMDA-receptors have been examined in this study and 
are therefore described in more detail. 
 
1.4.1 DOPAMINE RECEPTORS 
Five dopamine receptors have been cloned and pharmacologically classified in two  
receptor subfamilies; D1 and D2. The D1 subfamily comprises the D1 (or D1A) and D5 (or 
D1B) receptors, and are classified as D1-like receptors. The D2 subfamily includes the D2, 
D3, and D4 receptors, and are classified as D2-like receptors (Brusa, 1999; Jaber et al., 
1996). All five receptors are members of the large G-protein coupled receptor superfamily, 
consisting of seven transmembrane domains. The members of the same family share 
common characterics, such as their general folding pattern and structure, which govern 
receptor interactions with ligands, as well as with proteins of signal transduction pathways. 
The main difference between these receptor subfamilies, is that D1 like receptors stimulate 
adenylyl cyclase, while D2-like receptors inhibit the activity of adenylyl cyclase, as 
depicted in figure 1.11 (Jaber et al., 1996). 
 
 
Figure 1.11:   Agonist binding to D1-like receptors (D1 and D5) activates trimeric G-protein (αs, β, γ). This 
activates adenylyl cyclase (AC), which in turn catalyzes the conversion of ATP to cAMP, activating protein 
kinase. Binding of D2-like receptors (D2, D3 and D5) activates an inhibitory G-protein (αi, β, γ), thereby 
inhibiting adenylyl cyclase (Siegel G.J. et al., 1999). 
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As mentioned above D1-like receptors couple to Gs, a stimulatory G-protein, stimulating 
adenylyl cyclase, and have the classical D1 pharmacology. Activated adenylyl cyclase 
catalyzes the conversion of ATP to cyclic AMP (cAMP), which in turn causes dissociation 
of the regulatory and catalytic subunit of protein kinase A (PKA). This enzyme catalyzes 
conversion of protein substrates to phosphoproteins (Siegel G.J. et al., 1999). Although 
they share very high homology within their transmembrane domains, the D5 receptor has 
10-fold higher affinity for dopamine compared to D1(Jaber et al., 1996). The D1 receptor is 
the most widespread dopamine receptor and is expressed at a higher level than any other 
dopamine receptor, being found in the striatum, nucleus accumbens and olfactory tubercle. 
The D1 receptor is also found in the limbic system, hypothalamus and thalamus. The D5 
receptor is expressed at a much lower level than the D1 receptor, being restricted to the 
hippocampus (Jaber et al., 1996). Many D1 receptor interacting proteins have been 
described, amongst others calcyon, a single pass transmembrane protein thought to play an 
important role in D1 receptor Ca2+ signalling (Lezcano et al., 2000). 
 
The D2, D3 and D4 receptors are considered to be D2-like because of their homology and 
pharmacology. They are coupled to an inhibitory G-protein (Gi), and inhibit adenylyl 
cyclase. The D2 receptor is the dominating receptor of the D2-like receptors, and is found 
mainly in the neostriatum, olfactory tubercle and nucleus accumbens. The D3 and D4 
receptors are restricted to limbic areas (Jaber et al., 1996).  
 
1.4.2 N-METHYL-D-ASPARTATE RECEPTOR 
The N-methyl-D-aspartate (NMDA) receptor is an ionotropic, glutamate receptor which 
contains four transmembrane segments following a large extracellular domain (Moriyoshi 
et al., 1991). This receptor has binding sites for both glutamate and  modulatory glycine 
(Moriyoshi et al., 1991). 
 
There are six known NMDA- receptor subunit genes, encoding NMDA-1, NMDA-2A-
NMDA-2D and NMDA-3A subunits.The NMDA-1 subunit is regarded as an obligatory 
subunit since it is required for the formation of functional NMDA- receptor channels, while 
the NMDA-2 subunit is a modulatory subunit. The NMDA-3 subunit is expressed only in 
early development (Popescu, 2005; Stephenson, 2001). While glycine binds to the NMDA-
1 subunit, glutamate is bound to the NMDA-2 subunit (Popescu, 2005; Stephenson, 2001). 
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Functional NMDA-receptors are formed by the co-expression of NMDA-1 and NMDA-2 
subunits as shown in figure 1.12,  yielding receptors with different biophysical and 
pharmacological properties (Popescu, 2005; Stephenson, 2001). 
 
 
Figure 1.12 : A schematic diagram showing 
predicted transmembrane topology of an 
NMDA-1 (left) and NMDA-2 subunit where 
the N-terminal is extracellular (Stephenson, 
2001) 
 
 
 
 
 
 
 
NMDA receptors are expressed throughout the whole brain (Popescu, 2005; Stephenson, 
2001). High levels of NMDA receptors are implicated in seizures and neuronal loss, while 
low levels are implicated in schizophrenia, indicating it’s involvement in  neurological 
disorders (Moriyoshi et al., 1991; Stephenson, 2001). 
 
1.5 THE SYNAPSINS 
Synaptic vesicles are coated by synapsins, phosphoproteins that account for 9% of the 
vesicle protein (Kao et al., 1999; Rosahl et al., 1995). As described in chapter 1.1.2, these 
proteins are involved in the synaptic vesicle cycle (Sudhof, 2004). The synapsins are a 
family of neuron-specific proteins that are concentrated at synapses, where they are bound 
to the cytoplasmic surface of synaptic vesicles, by their N-terminal, as depicted in figure 
1.3 (Hosaka, Hammer, and Sudhof, 1999; Kao et al., 1999; Sudhof, 2004). 
 
In mammals, three synapsin genes, I, II, and III, have been cloned and characterized in 
human, mouse, and rat (Kao et al., 1998; Sudhof, 2004). The precise chromosomal 
locations of the genes for human and mouse synapsins I (Yang-Feng, DeGennaro, and 
Francke, 1986), II (Li et al., 1995a; Li et al., 1995c) and III (Kao et al., 1998) have now 
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been mapped. Human and mouse synapsin I map to the X chromosome, synapsin II maps 
to 3p25 and 6F, and synapsin III maps to 22q12.1 and 10, respectively. 
 
1.5.1 PRIMARY STRUCTURE AND PHYSIOCHEMICAL PROPERTIES OF THE 
SYNAPSINS 
Alternative splicing of the primary transcripts encoded by the three synapsin genes yields 
the five known synapsins: Ia, Ib, IIa, IIb and IIIa, as shown in figure 1.13. The differences 
between the ‘a’ and ‘b’ isoforms seem to be restricted to the C-terminal region (Ferreira 
and Rapoport, 2002). 
 
 
Figure 1.13 Mammalian 
domain model of the 
synapsins: Domains are 
schematically represented and 
indicated by letters A–J. The 
length of the polypeptide 
chains is shown at the top in 
number of amino acid residues 
(Kao et al., 1999). 
 
The common regions for all synapsin proteins are domains A to C, of nine known domains, 
as shown in figure 1.13 (domain A-J) (Kao et al., 1999; Valtorta, Benfenati, and 
Greengard, 1992). The domains E, F, H and I represent the portions of the molecules 
generated by alternative splicing (Valtorta, Benfenati, and Greengard, 1992), although 
domain E is a common component of both the synapsin Ia, synapsin IIa and synapsin IIIa 
isoforms (Ferreira and Rapoport, 2002). 
 
The different protein domains confer both to different function as well as different 
structural elements for synapsin proteins. In brief, domain A is a phosphorylation site for 
both cAMP-dependent protein kinase and Ca2+/calmodulin dependent protein kinase I 
(CaM kinase I)  (Hilfiker et al., 1999; Valtorta, Benfenati, and Greengard, 1992). Domain 
C exhibits the greatest similarity between synapsin proteins. The C domain binds ATP in 
all synapsin proteins and binds to other C-domains, mediating the formation of both homo- 
and heterodimers of synapsins(Ferreira and Rapoport, 2002; Valtorta, Benfenati, and 
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Greengard, 1992). Domain D is present only in synapsin I and contains two 
phosphorylation sites for CaM kinase II (Valtorta, Benfenati, and Greengard, 1992). 
 
1.5.2. THE FUNCTION OF THE SYNAPSINS 
Although the synapsins were among the first vesicle proteins to be discovered (Sudhof, 
2004), their functions still remain incompletely understood.  
 
The synapsin protein family is believed to play important roles in the generation and 
maintenance of synaptic vesicle clusters (Hilfiker et al., 1999). Many studies have shown 
that synapsins mediate the attachment of synaptic vesicles to actin filaments, and thereby 
regulate the amount of synaptic vesicles in the releasable pool. The interactions between 
synapsins and the cytoskeleton are reversible, due to phosphorylation of synapsins which 
decreases anchoring of synaptic vesicles to the cytoskeleton. Phosphorylation and 
dephosphorylation states of synapsins are suggested to affect the amount of synaptic 
vesicles being readily releasable or stored in reserve pool (Hilfiker et al., 1999; Valtorta, 
Benfenati, and Greengard, 1992). Synapsins may also modulate neuronal development, e.g. 
neurite elongation, establishment of neuronal polarity and synapse formation and 
maintenance, where each synapsin protein is involved at different stages of development  
(Bogen et al., 2006; Ferreira and Rapoport, 2002).  
 
1.6 ANIMAL MODELS  
In this study, two different animal models were used, namely synapsin I/II DKO mice, and 
an animal model for ADHD, Spontaneously Hypertensive Rat (SHR). Due to this reason 
gene knockout technology behind synapsin I/II DKO mice will be described as well as the 
breeding process behind SHR rats. 
 
1.6.1 GENE KNOCKOUT TECHNOLOGY 
Genetically engineered mice have become an invaluable biological tool for better 
understanding of physiological as well and pathological processes in biomedical research. 
In the field of neurosciences these animals have given a great contribution to shed light on 
basic mechanisms of brain function, e.g. elucidating physiological function of specific 
proteins such as receptors or intracellular mediators. In principle there are two ways to 
generate mutant mice, either by pronuclear microinjection or by homologous 
recombination in embryonic stem (ES) cells (Brusa, 1999). Since homologous 
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recombination was used for generation of the synapsin I/II DKO mice, this technique will 
be discussed further. 
 
The most widely used gene-targeting strategy is the production of complete loss-of-
function mutations (null mutations), or so called gene knockout (KO). In brief, a targeting 
vector carrying a selectable marker flanked by a sequence homologous to the genomic 
target gene  is constructed and introduced by transfection into an ES cell line. Cells in 
which homologous recombination has occurred are injected into host blastocysts, which are 
reimplanted in the uterus of peseudopregnant foster mothers (Brusa, 1999; Galli-Taliadoros 
et al., 1995; van der Neut, 1997). If ES cells contributed to the germ line the mutation is 
transmitted to the offspring and by subsequent matings homozygous mice are generated 
(Brusa, 1999).  
 
 
Figure 1.  Homologous recombination: The underlying concept of homologous recombination as described 
by Galli-Taliadoros et al. (1995)   
 
1.6.2 THE SPONTANEOUSLY HYPERTENSIVE RAT 
The spontaneously hypertensive rat (SHR) was developed in Kyoto, Japan, from the 
progenitor Wistar-Kyoto (WKY) rat by inbreeding 1. SHR is a commonly used animal 
model in studies of hypertension. During the inbreeding of the SHR for the high blood 
pressure trait, several behavioural characteristics were also seen, among others behavioural 
hyperactivity, increased beheavioral response to stressful stimuli, slower habitutation to 
novel stimuli and faster acquisition  of active avoidance (Sagvolden, Hendley, and 
Knardahl, 1992). 
 
                                                 
1 Inbreeding is breeding between close relatives, whether plant or animal. 
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It has repeatedly been suggested that SHR might be used as an animal model of Attention 
deficit disorder (ADHD) (Sagvolden, 2000; Sagvolden et al., 1992), a disorder prevalent 
during childhood, characterized by impared attention, excessive motor activity and 
impulsivity (Adriani et al., 2003). SHR develops response bursts similar to ADHD 
children, and although other strains and species may be hyperactive and/or show attention 
deficits following genetic, environmental or pharmacological interventions, the SHR is 
presently the only strain shown to have the major behavioral symptoms of ADHD 
(Sagvolden, 2000; Sagvolden and Sergeant, 1998). Since there are  many questions left 
regarding the ADHD disorder, SHR is of great importance in ADHD research. 
 
1.7 AIMS OF THE STUDY 
This study consists of two different parts. In the first part we have pursued the study of 
Bogen et al., (2006) with the main focus on what happens to levels of VAChT in mice 
devoid of synapsin I and II. Based on these findings, it was of interest to study if synapsin 
also serve a role in the cholinergic nervous system and therefore to see whether synapsin 
I/II DKO mice have changed levels of VAChT in the CNS and PNS, compared to their 
control wild-type (WT) mice. Three cholinergic brain areas/loci were selected, namely the 
neostriatum, cortex and pons medulla. The levels of other vesicular subgroups of synaptic 
vesicles, such as the glutamatergic and GABAergic vesicles, were also examined in these 
brain areas of synapsin I/II DKO mice.  
 
The aims of the second parts of the study were to determine the levels and possibly 
activities of proteins functionally related to specific neurotransmission systems in animal 
models for the “attention deficity hyperactivity syndrome” ADHD, SHR Due to that 
dopaminergic system has been hypothesized to be involved in the development of ADHD 
(Davids et al., 2003; Oades et al., 2005; Russell, 2003; Sagvolden et al., 2005), it was of 
interest to see whether the level of dopamine D1-receptor in SHR was changed in the 
neostriatum and cerebrum, and whether dopamine interacting proteins were changed as 
well. 
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2. MATERIALS AND METHODS 
 
2.1 MATERIALS 
Summary of chemicals and reagents, as well as content of buffers and solutions used in this 
assay are presented in the APPENDIX. 
 
2.2 ANIMALS 
Two different animal models were used in this study as indicated in 1.6. 
 
2.2.1 SYNAPSIN I/II DOUBLE KNOCKOUT MICE 
Mice devoid of synapsin I and II were obtained by homologous recombination as described 
in 1.5.1. The animals were a gift from Dr Paul Greengard (The Rockefeller University, NY, 
USA). The experimental animals were kept under conditions of constant temperature (22± 
2oC) and humidity (55 ± 5%), a 12 h light/dark cycle and free access to food and water.  
 
The animals were treated according to the Norwegian Animal Welfare Act and the 
European Communities Council Directive of 24 November 1986 (86/609/EEC). Efforts 
were made to minimize animal suffering and to reduce the number of animals used. 
 
2.2.2 SPONTANEOUS HYPERTENSIVE RATS 
25 Male Wistar Kyoto (WKY) and 25 Male Spontaneous Hypertensive Rats (SHR) were 
purchased from Harlan, England, and Charles River, Germany, respectively. 15 WKY and 
15 SHR were 4 weeks old, while 10 WKY and 10 SHR were 8 weeks old. The animals 
were kept under conditions of constant temperature (22± 2oC) and humidity (55 ± 5%), a 
12 h light/dark cycle and free access to food and water. 
  
The animals were treated according to the Norwegian Animal Welfare Act and the 
European Communities Council Directive of 24 November 1986 (86/609/EEC). Efforts 
were made to minimize animal suffering and to reduce the number of animals used. 
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2.3 SAMPLE PREPARATION 
Due to different laboratory methods various procedures for three sample preparations were 
carried out. These are as following:  
 
2.3.1 PREPARATION OF CRUDE HOMOGENATE FROM RATS DEVOID OF    
SYNAPSIN I AND II  
The neostriatum, pons/medulla oblongata and cerebral cortex, as well as the whole 
cerebrum, were dissected on ice and rapidly homogenized in 0.32M sucrose [5% 
homogenate (w/v)] in a glass-Teflon homogenizer at 450 rpm2. Samples were then added 
sodium dodecyl sulphate (SDS) (final concentration 1 %, w/v), boiled at 100oC for 3 
minutes, and stored at - 40oC. 
 
2.3.2 PREPARATION OF CRUDE HOMOGENATE FROM WKY AND SHR RATS 
Striatum and cerebrum were dissected on ice. They were rapidly homogenized in 0.32M 
sucrose [5% homogenate (w/v)] in a glass-Teflon homogenizer at 450 rpm. Samples were 
then added to SDS (final concentration 1 %, w/v), and stored at - 40oC. 
 
2.3.3 PREPARATIONS OF HOMOGENATE FROM DIAPHRAGM AND TONGUE  
Due to pilot studies that were carried out on vAChT and the synaptic vesicle protein 
synaptophysin in the peripheral nervous system of mice devoid of synapsin I and II 
proteins, different procedures for homogenate preparations of diaphragm and tongue were 
made, making it suitable for Western blotting.  
 
PROCEDURE 1 
Mice were killed by cervical dislocation. After dissection, both tongue and diaphragm were 
frozen on liquid nitrogen. Diaphragm and tongue muscles were cut with a razorblade, and 
homogenized in a glass-glass homogenizer at 450 rpm with homogenization buffer (0.32 M 
sucrose with 10mM HEPES and 1 mM EGTA). The homogenate (10% w/v) was 
centrifuged at 3000 rpm for 10 minutes, and the supernatant collected. To 200 µl sample, 
SDS was added (final concentration 1 %), sample was and stored at  -40oC. 
                                                 
2 rpm, or revolutions per minute,  is a unit commonly used to measure rotational speed in standard centrifuges 
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PROCEDURE 2 
Mice were killed by cervical dislocation. After dissection, both tongue and diaphragm were 
frozen on liquid nitrogen. Diaphragm and tongue muscles were cut with a razorblade, and 
homogenized in a glass-glass homogenizer at 450 rpm, with 0.03 % or 0.3 % Triton X-100 
added to WT and KO samples from both diaphragm and tongue (final concentration 10 %). 
Homogenate aliquots3 were centrifuged at 12 000 rpm for 20 minutes and supernatant 
collected. Supernatant was then added to SDS (final concentration 1 %), and stored at - 
40oC.  
 
PROCEDURE 3 
Mice were killed by cervical dislocation. After dissection, both tongue and diaphragm were 
frozen on liquid nitrogen. Diaphragm and tongue muscles were crushed in a mortar, and 
homogenized in 10mM HEPES in a glass-glass homogenizer rotating at 450 rpm, where 
three different diaphragms were combined, as well as three tongues from both WT and 
KO,. Homogenate was centrifuged at 9000 rpm for 10 minutes, the supernatant was 
collected and centrifuged at 400 000 rpm for 60 minutes. The pellet was re-suspended in 
dH20 with SDS (final concentration 1 %). The supernatant was also added to SDS (final 
concentration 1 %). Both pellet and supernatant were boiled at 100oC for 3-4 minutes, and 
stored at - 40oC. 
 
PROCEDURE 4 
Mice were killed by cervical dislocation After the dissection, both tongue and diaphragm 
were frozen on liquid nitrogen. Diaphragm and tongue muscles were cut with a razorblade, 
and homogenized in a glass-glass homogenizer at 450 rpm with TCA/acetone (final 
concentration 1.5 % for diaphragm samples, and 1 % tongue for tongue samples). In each 
tube, 500 µl 1M KCL was added, and left to stand for 10 minutes at 4oC. Homogenate was 
then centrifuged at 14 000 rpm for 5 minutes, supernatant flicked off and pellet of tongue 
and diaphragm sample re-suspended (into 0.5 ml and 1ml respectively of acetone/DTT/NaF 
(final concentration 10mM DTT, 20 mM NaF). Tubes were centrifuged again at 14 000 
rpm, supernatant flicked off, and pellets vacuum dried for 20 minutes. Pellet of tongue and 
diaphragm sample were re-suspended in respectively 200 µl and 400 µl of urea sample 
buffer (final concentration 20 mM Tris, 22 mM Glycine, 8M Urea and 10 mM DTT, (pH 
                                                 
3 One sample of KO of tongue and one sample of KO diaphragm were not centrifuged. 
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8.6). Samples were sonicated on ice 4 x 30 seconds, with 30 seconds between each 
sonication., left on for 2 h on rotor in 4oC, vortexing sample after 30 minutes and 1 hour 
and 15 minutes. Sonication step was repeated, and samples were sonicated 2 x 30 seconds, 
with 30 seconds between each sonication. Sample was sheared by passing it through ice 
cold needle, and afterwards centrifuged at 14 000 rpm for 2-3 minutes. Supernatant was 
removed to clean eppendorf tubes, and samples were frozen at -40oC.  
 
PROCEDURE 5 
Same procedure as in 2.2.3.3, except that diaphragm and tongue were homogenized in an 
UltraTurrax cutter _and protease inhibitor was added prior to homogenization, together 
with 10mM HEPES. 
 
2.4 PROTEIN DETERMINATION 
Protein concentration was determined as described in BCA TM Protein Assay Kit, Pierce, 
Rockford, IL, USA. In brief, BCATM Protein Assay is a detergent-compatible formulation 
based on bicinchoninic acid (BCA) for the colorimetric detection and quantification of total 
protein. Proteins reduce Cu2+ in alkaline solutions to Cu+. Two molecules BCA react with 
each Cu+ resulting in a red water soluble complex with an absorption maximum of 562 nm. 
Absorbance is proportional to the total protein concentration, which allows 
spectrophotometric quantification of protein in aqueous solutions. 
 
In every protein determination, we used a microplate procedure, with seven standards of 
bovine serum albumin (BSA) (0, 0.125 mg/ml, 0.25mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1.0 
mg/ml, 1.5 mg/ml) and four replicates of every sample. 200 µl of BCA–reagent was added 
in each well. 
        
2.5 WESTERN BLOTTING 
Western blotting is a method used for protein detection in a sample, after separation on a 
sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE). The basic blotting procedure 
can be divided into sample preparation, gel electrophoresis, membrane transfer, blocking 
non-specific binding, addition of the antibody and detection (Towbin et.al., 1979).  
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Samples are loaded into the wells on a gel, which in turn is placed in an electrode 
assembly. SDS-PAGE gel electrophoresis will then separate proteins in complex mixtures 
according to size. Using electrophoresis, proteins are then transferred on to a nitrocellulose 
filter. Primary antibody will then attach to an epitope of the protein of interest. Secondary 
antibody will then bind to the primary antibody. This antibody, which binds to the primary 
antibody, is coupled to an enzyme, horseradish peroxidase (HRP), The latter is detected 
using luminol solution. Active HRP enzyme catalyzes a reaction  with luminol, which 
thereby emits light which is detected on audoradiography film. 
 
2.5.1 GEL PREPARATION 
Two different gels were polymerized on top of each other: on top a stacking gel with a low 
amount of polyacrylamide for stacking the proteins before separation, and below a running 
gel with a higher amount of polyacrylamide for separation of the proteins. 
 
Stacking gel contained 5% polyacrylamide solution (from stock solution containing 30% 
Acrylamide/ Bis solution, BioRad, Richmond, CA) (final concentration nof 5 % gel: 15% 
polyacrylamide, 25 % Tris-HCl (pH 6.8)+0.4 % SDS, 0.6% ammonium persulfate (APS),  
0.2 % N,N,N′,N′-Tetramethylethylenediamine (TEMED)), and the running gel contained 
10% polyacrylamide/BIS  (final concentration of 10 % gel: 33% polyacrylamide, 25 % 
Tris-HCl (pH8.8)+0.4 % SDS, 0.3% APS,  0.1 % TEMED). 
  
Other solutions added to polyacrylamide while making both running and stacking gel are 
presented in APPENDIX. 
 
2.5.2 GEL ELECTROPHORESIS 
The gel cassette was assembled and running buffer was added to the upper reservoir, The 
samples, dissolved  in 1 % SDS, were added to sample buffer containing (final conc.) 2 % 
(w/w) SDS, 10 % (w/v) glycerol, 50 mM Tris/HCl (pH 6.8), 0.25 % (w/w) bromophenol 
blue, 0,1 M dithiothreitol), and equal amounts of total protein (10 µg/lane, determined by 
procedure described in 2.3) were applied to the individual lanes in the stacking gel. 
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We used protein standard (Precision Plus Protein Dual Color Standards, BioRad, 
Richmond, CA), as a reference to determine the molecular weight of proteins of interest 
identified by antibody probes. 
 
Gel electrophoresis was run at 120 volts in a running buffer (final concentration 0.64 M 
Glycine, 0.08 M Tris), for approximately 80-90 minutes, and stopped when the 
bromophenol blue dye front reached the bottom of the gel. 
  
2.5.3 MEMBRANE TRANSFER 
After gel electrophoresis, transfer of proteins from polyacrylamide gel to a nitrocellulose 
membrane (0.2 µm pore size, Bio-Rad Laboratories, Hercules, CA, USA) was 
accomplished by electroblotting. In this procedure, a sandwich of gel and solid support 
membrane is compressed in a cassette and immersed in buffer between two parallel 
electrodes. A current is passed at right angles to the gel, which causes the separated 
proteins to electrophorese out of the gel and onto the solid support membrane. Protein 
binding is based upon hydrophobic interactions, as well as charged interactions between the 
membrane and protein. This membrane is called “blot”.  
 
Sponges and filters, used in membrane transfer, were soaked in Towbin buffer (final 
concentration 0.13 M Tris and 0.4 M Glycine), and the transfer chambers were then 
assembled in the following order 
    
   (-) Black-plate – sponge – filter – gel – membrane – filter – sponge – transparent plate(+) 
 
(-) and (+) indicate anode and cathode respectively, as shown in figure 2.1. Proteins 
travelled from anode to cathode. 
 
Figure 2.1 Basic principle for  
membrane transfer 
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Protein transfer was run at 21 volts overnight in Towbin buffer. After the transfer was 
finished, 0.2 % Ponceau S was used (Salinovich and Montelaro, 1986) to control for 
efficient transfer of total proteins, by coloring proteins on the membrane. Ponceau S was 
then washed away with Tris-buffered saline solution with 0.05% Tween 20 (TBS-Tween) 
(final concentration 0.067M Tris, 0.46 M NaCl and 0.05 % Tween 20).  
 
2.5.4 BLOCKING NON SPECIFIC BINDING 
Since the membrane has been chosen for its ability to bind protein, steps must be taken to 
prevent non-specific protein interactions between it and the antibody used for detection of 
the target protein. Blocking of non-specific binding was achieved by placing the membrane 
in 5% non-fat dry milk in TBS-Tween, for 80-90 minutes at room temperature with gentle 
agitation. After the blocking step, the membrane was rinsed twice in TBS-Tween. 
 
2.5.5 ADDITION OF THE PRIMARY AND SECONDARY ANTIBODY 
Primary antibody was diluted in TBS-Tween according to the optimal dilution 
concentration of the antibody. The blots were incubated in primary antibody for 2 hours at 
room temperature, with gentle agitation or left overnight at temperature of 4oC. Following 
incubation in primary antibody the blots were washed 6 x 10 minutes, in TBS-Tween., 
before addition of secondary antibody. 
 
Secondary antibody was diluted in TBS-Tween, and blots were incubated for 60 minutes at 
room temperature with gentle agitation. Membrane was then washed 6 x 10 minutes in 
TBS-Tween. 
 
2.5.6 DETECTION 
Secondary antibodies used in this assay were conjugated to enzyme HRP. This enabled 
chemiluminescent detection reagent to emit light by being oxidized by this enzyme, and 
producing intense light emission, as shown in figure 2.2. In this study, the “Amersham 
ECL plus TM Western Blotting Detection reagent” was used, where acridinium ester, a 
chemiluminescent reagent, becomes oxidized. Immediately following oxidation, the 
acridinium ester is in an excited state which then decays to ground state via light emitting 
pathway.  
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Figure 2.2 Basic principle for chemiluminescence 
 
After the incubation in secondary antibody, blots were subsequently washed and incubated 
with the ECL plus TM. The signals were visualized on Hyperfilm MP (Amersham), and 
scanned in a desktop scanner (Scan Jet 3 c, Hewlett-Packard, Houston, TX, USA) at 600 
dpi.  
 
2.6 RECEPTOR BINDING ASSAY 
2.6.1 FUNDAMENTALS OF RECEPTOR BINDING ASSAY 
Radioligand binding analysis is a method used for studying receptors. There are three 
major types of experiments: saturation, kinetic, and inhibition. In this study, the experiment 
of interest was saturation binding experiment. . 
 
For binding sites to represent functional receptors the binding needs to be specific; which 
means that it has to be replaceable by relevant unlabelled ligand in a relatively low 
concentration range. All ligands, both agonist and antagonists, also have to inhibit the 
binding of the radioligand to the similar level of non-displaceable binding.  
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2.6.2 DEFINITION OF SPECIFIC BINDING 
TOTAL BINDING 
Total binding is the complete quantity of the radioactivity of sample. Total binding 
includes both specific binding of the radioactive ligand bound to receptor of interest, and 
nonspecific binding to any other component. 
  
NONSPECIFIC BINDING 
Nonspecific binding includes binding of the radioligand to other receptor sites, to glass 
fiber filters, adsorption to the tissue, and dissolution in the membrane lipids. In carrying out 
nonspecific binding, appropriate excess of unlabeled drug is applied (e.g. 100 times higher 
than the IC50) to block fully the receptors of interest (Bylund and Toews, 1993). 
 
SPECIFIC BINDING 
Specific binding can be defined as binding to the receptor of interest. Specific binding is 
calculated as the difference between the total binding and non-specific binding (Bylund and 
Toews, 1993). 
     
2.6.3 TISSUE PREPARATION 
Equipment and buffers were kept on ice during the tissue preparation. Centrifugations were 
carried out at 4oC, to avoid loss of binding activity.Membrane preparation was made as 
previously published (Kontur et al., 1994) with minor adjustments. 
 
Male rats (WKY/SHR) were anesthetized with carbon dioxide. Following decapitation, the 
brain was rapidly removed and placed on ice, where 10 WKY and 10 SHR rats were two 
months of age, and 15 WKY and 15 SHR rats were one months of age. The striatum was 
dissected from 34 rats, while cerebrum was dissected from 16 rats.  Brains were divided by 
a sagittal cut, and hemibrains were obtained from 10 rats, while whole cerebrum was 
removed from 6 rats. Due to a small volume, two and two striata of WKY and SHR rats 
respectively, were combined from a total of 24 rats. 
 
After dissection, brain samples were washed in ice-cold 50 mM Tris-HCl (pH 7.4) buffer to 
remove hair and blood, and then homogenized in 15 volumes 50 mM Tris-HCl buffer for 
30 seconds with a glass-Teflon homogenizer. 
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This homogenate was centrifuged at 3500 rpm for 10 minutes. Supernatant was collected 
and centrifuged at 13500 rpm for 20 minutes, and the pellet was rehomogenized in 10 
volumes Tris-HCl buffer for 15 seconds. In order to remove endogenous ligands, the 
membranes were incubated for 30 minutes at 37oC followed by another centrifugation for 
20 minutes at 13 500 rpm, after which the pellet was rehomogenized in 10 volumes buffer  
(50 mM Tris-HCl (pH 7.4), 120 mM NaCl, 5 mM KCl, 2 mM CaCl2  and 1 mM MgCl2 ). 
Following rehomogenization, the membrane suspension was frozen in liquid nitrogen, and 
stored at -80oC. 
 
2.6.4 LIGANDS AND THE EXPERIMENTAL CONDITIONS FOR RECEPTOR 
BINDING ASSAY 
For the analysis of D1 antagonist binding, previously published method as described by 
(Kontur et al., 1994; von Euler, 1991) were used, with minor adjustments. 
 
The selected radioligand in this study was the D1-antagonist [N-methyl-3H] SCH23390 
(Amersham Biosciences) (figure 2.3) (Kontur et al., 1994; von Euler, 1991) 
 
 
 
Figure 2.3 Structural formula: [N-methyl-3H] SCH23390. The 
bold hydrogen atoms (H) in the circle  represent the 3H in the 
structural formula.CH2[3H] 
 
 
 
 
 
The non-specific binding was defined as the binding in the presence of SCH23390 
hydrochloride. 
 
To find a suitable amount of membrane homogenate and radioactive ligand concentration 
to be used in receptor assay, different concentrations and volumes of the membrane 
homogenate were tested. 
 
 
 39
TEST 1: 
Different concentrations of the radioactive ligand [3H] SCH 23390 (0,5nM, 1nM, 2 nm, 
5 nM, 10 nM) were tested, using the same method as indicated in receptor binding assay 
below. 200 µl membrane suspension from one sample was used. 
        
TEST 2:    
Different amounts of membrane suspension were used (100µl, 200µl and 300µl), with two 
different radioactive ligand concentration (1 nM, 2 nM). Rest of the method was followed 
as indicated in receptor binding assay below. 
      
   
2.6.5 RECEPTOR BINDING ASSAY  
Assay tubes containing 150-300 µl of either cerebrum homogenate, or  100µl of striatal 
homogenate, with Tris-HCl buffer and ketanserine (100 nM), were preincubated with non-
specific SCH 23990 (0.5-1 µM), for 10 minutes at 25oC. After the preincubation 50 µl 
radioactive ligand [3H] SCH 23390 was added, and the incubation continued for 30 minutes 
at 25 oC. The incubation was terminated by rapid filtration followed by  three washings 
with 5 ml of ice-cold 50mM Tris-HCl buffer  through GF/C-filters (25 mm glassmicrofiber 
filter, Wathman ® , England) using a filtering box. Filters were presoaked for 20-60 
minutes in 0.5% polyethylenimine to decrease nonspecific binding to the filter. Filters were 
counted for radioactivity by liquid scintillation spectrometry (Packard 1900 TR) in 4 ml 
Filter Count Scintillation Fluid (Packard Instrument Co.).  
     
2.7 STATISTICS 
Results were represented as mean ± S.E.M. The significance of differences in levels of 
proteins between synapsin DKO and WT mice or WKY and SHR rats, as well us 
differences in amounts of D1 receptors in WKY and SHR rats were assessed on raw data by 
Student’s t-test. Differences were considered statistically significant when P<0.05 
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3. RESULTS 
 
This study consists of two parts. In the first part the levels of vesicular proteins in different 
brain regions of synapsin I/II DKO mice were examined. In the second part studies on the 
dopaminergic system in an animal model for ADHD were done. 
 
3.1 THE LEVEL OF VESICULAR PROTEINS IN THREE BRAIN 
REGIONS OF SYNAPSIN I/II DKO MICE 
 
A reduction in the levels of several transporter proteins in forebrain of mice devoid of 
synapsin I and II, such as VGLUT-1, VGLUT-2 and VGAT, has been described by our 
group (Bogen et al., 2006). In this study, we have focused on the cholinergic nervous 
system of synapsin I/II DKO mice, studying the levels of vesicular acetylcholine 
transporter both in the central and peripheral nervous system. It was of interest to find 
whether this phenomenon could be assessed on three different cholinergic regions, namely 
neostriatum, cortex and pons medulla. Further, the amount of transporter protein for 
acetylcholine, VAChT and GABA enzyme, GAD65 were also examined, to see whether 
the amounts of proteins are altered in these brain sections. Western blotting, as described in 
chapter 2.5, was used to detect the amount of the different proteins in the following studies. 
 
In addition, the level of different vesicular proteins found in neostriatum, cortex and pons 
medulla in WT mice, was compared to the level found in cerebrum in WT mice. 
 
3.1.1 VESICULAR ACETYLCHOLINE TRANSPORTER 
  
The vesicular acetylcholine transporter, VAChT, was examined in neostriatum, cortex, 
pons medulla and cerebrum, in WT and synapsin I/II DKO mice. The level of VAChT was 
decreased by approximately 20% in neostriatum in synapsin DKO mice, as shown in table 
3.1. In contrast, no significant difference was found in the other brain areas studied. 
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Table 3.1: The level of VAChT in neostriatum, cortex, pons medulla and cerebrum in synapsin I/II DKO 
mice were quantified by Western blotting. The molecular mass, in kilo Dalton (kDA), is indicated to the left 
of the immunoblot. Results are expressed as percent of mean levels in WT.  Data are shown as mean ± SEM 
from 4-7 animals of each genotype. The immunoblot shown is representative of 4-7 experiments. *** p < 
0.005 by paired Student’s t-test. 
        Pons  
Primary   Pons  Molecular Neostriatum Cortex Medulla Cerebrum 
antibody Neostriatum Cortex Medulla 
 
Cerebrum
mass 
(kDa) 
WT     DKO WT   DKO WT   DKO WT  DKO 
          
75- 
    
 
 
 
    
VAChT 77 ± 2 *** 94 ± 4 84 ± 7 
 
101 ± 4 
 
    
     50-     
          
 
 
3.1.2 VESICULAR GLUTAMATE TRANSPORTER 
 
The levels of VGLUT-1, VGLUT-2 and VGLUT-3 were measured in neostriatum, cortex, 
pons medulla as well as in cerebrum, in WT and synapsin I/II DKO mice. As shown in 
table 3.2 a 40% reduction in VGLUT-1, per total mg protein was found in cerebrum from 
synapsin I/II DKO mice. This compares well with the reduction per mg protein in both 
cortex and neostriatum, with approximately 30 and 40% decrease, respectively. The level 
of VGLUT-1 in pons medulla was too weak to be detected, relatively to the other brain 
areas studied. 
 
The levels of VGLUT-2 in cerebrum from synapsin DKO mice were decreased to 66% of 
WT levels. This finding compares well with the approximate 50% reduction per total mg 
protein in neostriatum, and by the 40% decrease in cortex and pons medulla, respectively.  
 
In contrast to the other two glutamate transporters, the level of VGLUT-3 per mg protein in 
cerebrum, neostriatum, and cortex and pons medulla was unchanged, as shown in table 3.2. 
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Table 3.2:  Levels of VGLUT-1, VGLUT-2 and VGLUT-3 in neostriatum, cortex, pons medulla and 
cerebrum in synapsin I/II DKO mice were quantified by Western blotting. The molecular mass, in kilo Dalton 
(kDA), is indicated to the left of the immunoblot. Results are expressed as percent of mean levels in WT.  
Data are shown as mean ± SEM of 5-9 animals of each genotype. The immunoblots shown are representative 
from 5-9 experiments. * p < 0.05, *** p < 0.001 by paired Student’s t-test. 
        Pons  
Primary   Pons  Molecular Neostriatum Cortex Medulla Cerebrum 
antibody Neostriatum Cortex Medulla 
 
Cerebrum
mass 
(kDa) 
WT     DKO WT  DKO WT   DKO WT      DKO 
 
   Not 
 
75- 
 
 
   
VGLUT-1 63 ± 4 *** 70 ± 3* detectable 61 ± 6*      
     50-     
     
 
75- 
 
    
VGLUT-2 52 ± 6 * 63 ± 4 * 63± 6 * 66 ± 3 *      
     50-     
75- 
      
 
 
   
VGLUT-3 90 ± 5 101 ± 7 86 ± 14 110 ± 14 50-     
 
 
3.1.3 VESICULAR GABA TRANSPORTER 
 
The vesicular GABA-transporter, VGAT, was examined in neostriatum, cortex, pons 
medulla and cerebrum, in WT and synapsin I/II DKO mice. The level of VGAT was 
decreased to 61% in neostriatum, 76% in cortex, 77% in pons medulla and compared well 
with the findings in cerebrum.  
 
 
Table 3.3:  The level of VGAT in neostriatum, cortex, pons medulla and cerebrum in synapsin I/II DKO 
mice were quantified by Western blotting. The molecular mass, in kilo Dalton (kDA), is indicated to the left 
of the immunoblot. Results are expressed as percent of mean levels in WT.  Data are shown as mean ± SEM 
from 4-6 animals of each genotype. The immunoblot shown is representative of 3-6 experiments. * p < 0.05 
by paired Student’s t-test. 
    
  
  Pons  
Primary   Pons 
  
Molecular Neostriatum Cortex Medulla Cerebrum 
antibody Neostriatum Cortex Medulla 
 
Cerebrum
mass 
(kDa) WT     DKO WT  DKO WT   DKO WT   DKO 
75- 
    
 
     
VGAT 61 ± 7* 76 ± 6* 77 ± 3* 
 
74± 4 * 
 
     50- 
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3.1.4 SYNAPTOPHYSIN 
 
Synaptophysin was used as a vesicular marker to measure the total level of synaptic 
vesicles. This was done both in the central and peripheral nervous system. The level of 
synaptophysin was measured in neostriatum, cortex, pons medulla as well as in cerebrum, 
in WT and synapsin I/II DKO mice. Table 3.4 shows a decrease by 66% of synaptophysin 
per mg protein in cerebrum from synapsin I/II DKO mice. This compares well with the 
reduction per total mg protein in neostriatum, cortex and pons medulla, where a decrease 
by 56%, 41% and 59% was detected, respectively. 
 
 
Table 3.4: The level of synaptophysin  in neostriatum, cortex, pons medulla and cerebrum in synapsin I/II 
DKO mice were quantified by Western blotting. The molecular mass, in kilo Dalton (kDA), is indicated to 
the left of the immunoblot. Results are expressed as percent of mean levels in WT.  Data are shown as mean ± 
SEM from 4-7 animals of each genotype. The immunoblot shown are representative of 4-7 experiments.  **p 
< 0.01 *** p < 0.005 by paired Student’s t-test. 
        Pons  
Primary   Pons  Molecular Neostriatum Cortex Medulla Cerebrum 
antibody Neostriatum Cortex Medulla 
Cerebrum mass 
(kDa) 
WT     DKO WT   DKO WT DKO WT  DKO 
50- 
    
 
     
synaptophysin 44 ± 8*** 59 ± 5*** 41 ± 4*** 34 ± 7**  
     37- 
      
 
 
 
3.1.5 GLUTAMIC ACID DECARBOXYLASE  
 
GAD65 is an enzyme responsible for generation of GABA. GAD65 was examined in the 
neostriatum, cortex, pons medulla and cerebrum in WT and synapsin I/II DKO mice. Two 
bands were detected between 50 and 75 kDa, as shown in table 3.5, and both signals were 
quantified. No difference was found in the level of GAD65 in WT and mice devoid of 
synapsin I and II. Although a decrease by 20% was found in pons medulla, this was found 
not to be statistically significant (p-value 0.052). 
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Table 3.5: The level of GAD65 in neostriatum, cortex, pons medulla and cerebrum in synapsin I/II DKO 
mice were quantified by Western blotting. The molecular mass, in kilo Dalton (kDA), is indicated to the left 
of the immunoblot. Results are expressed as percent of mean levels in WT.  Data are shown as mean ± SEM 
from 4 animals of each genotype. The immunoblot shown is representative of 4 experiments.   
        Pons  
Primary   Pons  Molecular Neostriatum Cortex Medulla Cerebrum 
antibody Neostriatum Cortex Medulla 
Cerebrum mass 
(kDa) WT     DKO 
WT   
DKO WT   DKO WT    DKO 
75- 
    
 
 
 
 
   
GAD65 92 ± 4 99 ± 5 78 ± 4 95 ± 12      
     50-     
          
 
 
3.1.6 THE LEVELS OF CHOLINERGIC VESICLES IN PHERIPHERAL 
NEURONS IN SYNAPSIN I/II DKO 
As described in chapter 2.3.3, different procedures were used for homogenate preparation 
of diaphragm and tongue, making it suitable for detecting VAChT by Western blotting. 
 
Procedure 1 was a suitable method for making homogenate of diaphragm and tongue, and 
hereby for detecting by Western blotting, as shown by films in table 3.6. In contrast to 
previous blot of unclear VAChT in CNS, two bands were detected in the peripheral 
nervous tissue, having approximately 70 kDa molecular mass, as shown in table 3.6. 
Therefore both of the signals were quantified.   A reduction with approximately 15 % was 
seen in diaphragm in mice devoid of synapsin I and II. No difference was found in the 
amount of VAChT in tongue. Due to few parallels, statistics were not calculated here. 
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Table 3.6:  The level of VAChT in diaphragm and tongue in synapsin I/II DKO mice were quantified by 
Western blotting on fractions made by procedure 1. The molecular mass, in kilo Dalton (kDA), is indicated to 
the left of the immunoblot. Results are expressed as percent of mean levels in WT (WT) animals.  Data are 
shown as mean ± SEM from 3-4 animals of each genotype. The immunoblots shown are representative of 1-3 
experiments.  
 
Primary       
Antibody       
  Molecular     
VAChT  
mass 
(kDa) 
WT4  
DKO WT     DKO WT   DKO WT5 DKO
75- 
 
 
Diaphragm 85 ± 7      
 
  50-     
Tongue 94 ± 1 75- 
 
    
       
       
  50-     
 
 
In addition to procedure 1, procedure 5 gave suitable homogenates of both diaphragm and 
tongue, for detecting VAChT by Western blotting as indicated by the films shown in table 
xxx. In contrast to the samples prepared by procedure 1, a single, distinct band at 
approximately 70 kDa was detected. Table 3.7 indicates that the amount of VAChT in 
diaphragm was not statistically different in DKO mice compared to WT mice. There was 
an increase by approximately 11% in the tongue samples in synapsin DKO, compared to 
WT. Due to few parallels, statistics were not calculated here. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
4 Lane 1 of diaphragm was not quantified due to unclear signal 
 
5 Lane 7 of both diaphragm and tongue was not quantified due to unclear signals 
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Table 3.7:  The level of VAChT in diaphragm and tongue in synapsin I/II DKO mice were quantified by 
Western blotting, on fractions made by procedure 5. The molecular mass, in kilo Dalton (kDA), is indicated 
to the left of the immunoblot.Results are expressed as percent of mean levels in WT (WT) animals. Data are 
shown as mean ± SEM from 2-3 animals of each genotype. The immunoblots shown are representative of 1-2 
experiments.  
Primary     
Antibody     
  Molecular   
VAChT  mass (kDa) WT     DKO WT      DKO 
Diaphragm 99 ± 6    
75- 
 
 
  
  50-   
Tongue 111 ± 0.13 75- 
 
  
     
  50-   
 
 
Although the same antibody was used on samples prepared by procedure 1 and procedure 
5, two bands were found using procedure 1, in contrast to a single band when using 
samples prepared by procedure 5. The manufacturer of this VAChT antibody claims that 
this is a common phenomenon for large glycoproteins, e.g. VAChT, resulting in various 
signals. This can be due to the other proteins interacting with this vesicular transporter, e.g. 
myosin and actin (personal announcement by  Henrik Martens from the manufacturer 
SYSY,). 
  
Procedures 2-4, described in chapter 2.3.3, were not suitable methods for sample 
preparation for detection of the amount of VAChT in diaphragm and tongue by western 
blotting (films and data not shown).  
 
 
I addition to VAChT, different procedures for sample preparation were tested to detect the 
amount of synaptophysin in the peripheral nervous system, as described in chapter 2.3.3. 
None of the procedures tested were suitable for detecting synaptophysin in diaphragm and 
tongue at the expected molecular weight (films and data not shown). 
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3.2 RELATIVE LEVELS OF DIFFERENT VESICULAR PROTEINS IN 
NEOSTRIATUM, CORTEX AND PONS MEDULLA COMPARED TO 
LEVELS IN THE CEREBRUM 
 
The levels of different vesicular proteins in neostriatum, cortex and pons medulla in WT 
mice were compared to the levels found in total forebrain. The following comparison 
between levels in different brain regions and levels in total brain, are performed in WT 
animals using crude date from Western blotting experiments described in chapter 3.1. 
 
Table 3.8: Relative levels of different vesicular transporters, synaptophysin and GAD65 in the neostriatum, 
cortex and pons medulla, compared to average levels in total cerebrum in WT mice. Results shown are 
expressed as percent of mean levels in cerebrum. Data are shown as means ± SEM from a total of 3-7 
experiments, using crude data from experiments described in chapter 3.1.  * p < 0.05 by paired Student’s t-
test. 
      
Primary     
  Pons 
antibody Cerebrum Neostriatum Cortex Medulla 
VGLUT-1 100 92 ± 9 116 ± 13 
 
No 
signal 
detected 
      
VGLUT-2 100 90 ± 9 77 ± 6 145 ± 9 
      
VGLUT-3 100 285 ± 35 125 ± 18 73 ± 21 
     
VGAT 100 80 ± 6 87 ± 17 106 ± 25 
     
VAChT 100 182 ± 15 103 ± 10 72 ± 6 
     
Synaptophysin 100 129 ± 30 120 ± 21 46 ± 6 * 
     
GAD65 100 85 ± 13 89 ± 13 110 ± 13 
 
No signal of VGLUT-1 was detected in pons medulla related to the cerebrum in WT. 
Although found statistically non significant, a 45% higher amount of VGLUT-2 was seen 
in pons medulla related to the cerebrum in WT. The level of VGLUT-3 was almost a 3 fold 
higher in neostriatum compared to cerebrum, but this was found non significant. 
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No significant differences were found in the levels of VGAT in cortex and pons medulla in 
WT mice, compared to the level in cerebrum, as shown in table 3.8. The level of VGAT in 
neostriatum was 20% lower in neostriatum compared to the level in cerebrum.  
 
The level of VAChT in the neostriatum was 1.8-fold higher compared to cerebrum in WT 
mice. This difference in VAChT level was however not statistically significant. In contrast 
to neostriatum, the level of VAChT in pons medulla was 28% lower compared to 
cerebrum, albeit this was also found no significant. 
 
The level of synaptophysin was 50% lower in pons medulla than the level found in 
cerebrum. This difference was found statistically significant. In contrast, the levels of 
synaptophysin in neostriatum and cortex were slightly higher compared to the average level 
in total cerebrum. 
 
As shown in table 3.8 the levels of GAD65 were found to be evenly distributed in striatum, 
cortex and pons-medulla, as compared to the levels in total forebrain.  
 
3.3 STUDIES ON THE DOPAMINERGIC SYSTEM IN AN ANIMAL 
       MODEL FOR ADHD 
 
SHR is the only animal model that has been shown to demonstrate all of the behavioural 
characteristics of ADHD, namely hyperactivity, impulsivity and problems with sustained 
attention (Sagvolden, 2000; Sagvolden et al., 1992). In chapter 3.3.1 and 3.3.2 studies of 
D1/D5 receptor binding in SHR compared to control rats are described. In chapter 3.3.3, the 
levels of different proteins possibly involved in dopaminergic dysfunction are compared in 
SHR and WKY rats. 
 
3.3.1 D1/D5 RECEPTOR BINDING IN SHR 
Different tests were performed to find a suitable amount of the radioactive ligand 
concentration and amount of membrane homogenate to be used in D1/D5 receptor binding, 
as described in chapter 2.6.4 
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3.3.1.1 Method testing 
 TEST 1: 
[3H] SCH23390 binds selectively to dopamine D1-like receptors (D1 and D5), and was 
added in increasing concentrations (0.5-10 nM). Non-specific binding was measured by 
addition of unlabelled SCH23390 (final concentration 1 µM). Binding was highest at 
concentrations between 0.5 and 2 nM. 
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Figure 3.1: Binding of [3H] SCH23390 in cerebrum homogenate with increasing ligand concentrations 
(0.5-10 nM) alone or in combination with 1 µM SCH23390. Specific binding was calculated as the 
difference between the total binding and non specific binding. Data shown represents two independent 
experiments. 
 
 
 
TEST 2 : 
 
As shown in Figure 3.1 the highest degree of specific binding was found with ligand 
concentrations ranging from 0.5-2 nM. Due to the small difference between specific and 
non specific binding for 1 and 2 nM, these concentrations were tested with increasing 
amount of membrane homogenate (figure 3.2) 
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Figure 3.2: Different amounts of membrane homogenate were incubated with two concentrations of [3H] 
SCH23390 (1 nM and 2 nM), either alone (total binding) or in combination with 1 µM SCH23390 (non 
specific binding). Specific binding was calculated as the difference between the total binding and non-
specific binding.  
 
 
 
3.3.2 DOPAMINE D1- LIKE RECEPTOR IN CEREBRUM AND STRIATUM 
 
Binding to D1-like receptors (D1 and D5 )  was significantly increased by approximately 
20% in SHR rats compared to WKY rats, using 0.5 nM [3H] SCH23390. A similar result 
was found for 1 nM, but this was however not significant due to a larger data variation, or 
few replicates. 
 
Table 3.9: Specific binding of [3H] SCH23390 to dopamine D1-like receptors measured in cerebrum. Results 
are expressed as percent levels of WKY animals per mg protein. Data are represented as mean ± S.E.M of 6-7 
animals of each genotype. * p < 0.05 by   paired Student’s t-test. The control levels for ligand binding was 
0.72 (0.5 nM) and 0.83 (1.0 nM) pmol/min/µg.   
 
        
                  % specific binding to  D1 receptor in SHR rats in proportion 
to the    control WKY 
       
           
concentration of the 
radioactive ligand  [3H] 
SCH23390  
% specific 
binding p-value 
 
 
pmol/min/µg
         
0.5 nM    121 ± 6 * 0.030 WKY: 0.72 
       
1.0 nM    118 ± 7 0.061 WKY: 1.43 
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A non significant reduction was seen in [3H] SCH23390 binding to D1-like receptors (D1 
and D5 ) in neostriatum membrane homogenate isolated from SHR compared to WKY.  
 
Table 3.10: Specific binding of [3H] SCH23390 to dopamine D1–like receptors measured at 1 nM in 
neostriatum being combined from two animals for 6 experiments, or not for 5 experiments. The data are 
correlated for protein, control level for binding of ligand was 1.9 pmol/min/µg. Results are expressed as 
percent level of WKY animals (mean ± S.E.M )of 11 animals of each genotype. The specific activity of the 
radioactive ligand bound in SHR and WKY animals are also expressed in pmol/min/µg  
 
       
% specific binding to D1 receptor in SHR rats in proportion to control WKY 
           
concentration of the radioactive 
ligand  [3H] SCH23390   % specific binding p-value pmol/min/µg
        
1.0 nM    93 ± 12 0.675 WKY: 1.9 
       
 
 
3.3.3 CALCYON, COMT AND NMDA-RECEPTOR SUBUNITS 
 
SHR was used in this study, to compare the levels of two proteins possibly involved in 
dopaminergic dysfunction, namely calcyon and COMT, with the levels in WKY rats. 
Further, the levels NMDA-Receptors were compared in SHR and WKY rats. Western 
blotting, as described in chapter 2.5, was used in the following studies. 
 
The amount of the D1-dopamine receptor interacting protein, calcyon, was examined in the 
neostriatum and cerebrum from SHR and compared to the levels in WKY rats. No 
difference in the amount of calcyon per mg protein was found in SHR rats compared to 
WKY in the neostriatum, nor in the cerebrum (table 3.11).  
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Table 3.11: Levels of calcyon in SHR rats in neostriatum and cerebrum were determined by Western 
blotting.  Results are expressed as percent of mean levels in WKY animals.  Data shown are expressed as 
mean ± SEM of 4 animals of each genotype. Immunoblots shown are representative of 4 experiments. 
 
Primary       
Antibody  Molecular     
  mass     
Calcyon  (kDa) WKY  SHR WKY  SHR WKY    SHR WKY SHR 
50- 
Neostriatum 104 ± 7  
 
   
  
37-  
    
Cerebrum 111 ± 6 
50-  
    
       
  37-     
       
 
 
 
COMT is an enzyme responsible for inactivation of catecholamines, e.g. dopamine. The 
amount of COMT was examined in the neostriatum and cerebrum from SHR and compared 
to the levels of proteins in WKY rats.  
 
Two bands were detected using the COMT antibody. The lower signal, represented a 24 
kDa soluble COMT, and the upper signal at 28 kDa represented membrane bound COMT. 
Both of the signals were quantified, since total COMT was of our interest. As shown in 
table 3.12, no significant difference in the level of COMT was found in neostriatum, nor in 
cerebrum in SHR rats, compared to WKY rats. The level of COMT per mg protein was the 
same in WKY and SHR. The signals of COMT in this study showed great variations, as 
shown in table 3.12. 
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Table 3.12: Levels of COMT in SHR rats in neostriatum and cerebrum were determined by Western blotting. 
Results are expressed as percent of mean levels in WKY animals.  Data shown are expressed as mean ± SEM 
of 5 animals of each genotype. Immunoblots shown are representative of 5 experiments. 
 
Primary       
Antibody  Molecular     
  mass     
COMT  (kDa) WKY     SHR WKY6  SHR WKY   SHR WKY   SHR 
       
25- 
   
 
    
Neostriatum 93 ± 2 20-     
       
Cerebrum 105 ± 2 
25-  
    
  20-     
 
 
 
There is an interaction between NMDA receptors and dopamine D1-like receptors (D1 and 
D5) (Cepeda and Levine, 2006; Lee and Liu, 2004). Since dopaminergic dysfunction is 
reported in SHR (Davids et al., 2003; Oades et al., 2005; Russell, 2003; Sagvolden et al., 
2005),  the NMDA-1 receptor subunits, required for  NMDA receptor activity, was 
examined in neostriatum and cerebrum of SHR and compared to WKY animals.  
   
The NMDA-1 receptor subunit-antibody generated the one band as shown in table 3.13. 
The amount of NDMA-R1 subunit detected in SHR were nearly identical to the amount 
detected in WKY rats, in both neostriatum and cerebrum, indicating that there is no 
difference in SHR rats in expression of this receptor subunit protein 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
6 Lane 3 of  neostriatum, WKY was not quantified due to a contaminated sample 
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Table 3.13: Levels of NMDA-1 receptor subunit in SHR rats in neostriatum and cerebrum were determined 
by Western blotting.  Results are expressed as percent of mean levels in WKY animals.  Data shown are 
expressed as mean ± SEM of 5 animals of each genotype. Immunoblots shown are representative of 5 
experiments. 
 
Primary       
Antibody  Molecular     
  mass     
NMDA-1  (kDa) WKY   SHR WKY 7 SHR WKY SHR WKY SHR 
150- 
   
 
 
   
Neostriatum 95 ± 5 100-     
       
  150-     
Cerebrum 98 ± 8  
 
    
  100-     
          
 
 
 
 
The levels of the NMDA-2A/B receptor subunit was quantified in neostriatum and 
cerebrum of SHR and compared to the levels in WKY animals. The amount of NMDA-
2A/B subunit of SHR compared to their control WKY, was the same in both neostriatum 
and cerebrum.  
 
Table 3.14: Levels of NMDA-2A/B subunit in SHR in neostriatum, and cerebrum, were determined by 
Western blotting. Results are expressed as percent of mean levels in WKY animals.  Data shown are 
expressed as mean ± SEM of 3-5 animals of each genotype. Immunoblots shown are representative of 3-5 
experiments. 
 
Primary       
Antibody  Molecular     
  mass     
NMDA-2  (kDa) WKY  SHR WKY     SHR WKY SHR WKY  SHR 
250- 
   
 
   
Striatum 101 ± 6 
 
150- 
 
    
Cerebrum 106 ± 3 
 
250-     
       
  
 
150-     
 
                                                 
7 Lane 3 of cerebrum, WKY, was not quantified due to sample contaminations. 
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4. DISCUSSION 
 
In this study, two different animal models with implications for neurological disorders have 
been examined. In the first part, the aim was to observe the consequences of deletion of 
synapsin I and II for different vesicular subgroups of vesicles in different brain regions. 
The effects on the cholinergic vesicles were of our main interest since the consequences of 
absence of synapsin I and II for this particular subgroup of vesicles have previously not 
been studied. 
 
In the second part, the aim was to measure the levels of proteins involved in the 
dopaminergic system in spontaneous hypertensive rats (SHR), serving as an animal models 
for the “attention deficity hyperactivity disorder” (ADHD). Since many dopaminergic 
effects are mediated through the interaction with glutamatergic neurotransmission, levels of 
different NMDA-receptor subunits were also examined.  
 
 
4.1 THE LEVEL OF VESICULAR PROTEINS IN SYNAPSIN I/II 
DOUBLE KNOCKOUT MICE 
This study is based on the results of Bogen et al., (2006), with the main focus on the effects 
on cholinergic vesicles when synapsin I and II are absent. VAChT was used as a marker for 
cholinergic vesicles and was quantified in three different cholinergic centra, namely the 
neostriatum, cortex and pons medulla. This is due to that neostriatum contains cholinergic 
interneurons, cortex have long cholinergic fibers originating in the nucleaus basalis and  
pons medulla project cholinergic terminals. 
  
4.1.1 THE LEVELS OF VESICULAR TRANSPORTERS IN SYNAPSIN I/II 
DOUBLE KNOCKOUT MICE IN CENTRAL NERVOUS SYSTEM 
VAChT was examined in synapsin I/II DKO mice to detect whether there was a change in 
the levels of the transporter responsible for transporting ACh into synaptic vesicles. A 
decrease by 23% was found in the neostriatum of synapsin DKO mice compared to wild-
type, while no difference was found in the cortex, pons medulla or whole forebrain. These 
results indicate that lack of synapsin I and II is of importance for the interneurons in the 
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striatum, while the cholinergic vesicles in cortex, pons medulla and total forebrain are 
unaffected. 
 
Both VGLUT-1, VGLUT-2 and VGAT were decreased by approximately 30-50% in 
neostriatum, cortex and whole cerebrum of synapsin I/II DKO. The levels of VGLUT-1 in 
pons medulla were to low to be quantified, while the levels of VGLUT-2 and VGAT were 
decreased to 63% and 77%, respectively, in pons medulla in synapsin I/II DKO. In 
contrast, no decrease was found in VGLUT-3 containing vesicles in neither of the 
examined brain areas. The general vesicle marker, synaptophysin, was decreased by 
approximately 40-60% in different brain areas, indicating a 40-60% decrease in the number 
of synaptic vesicles in synapsin DKO mice. This compares well with a 50% decrease in 
number of vesicles in synapsin DKO mice obtained by electron microscopy by Rosahl 
et.al., (1995) and 40% decrease detected in the levels of different general vesicle markers 
by Bogen et al., (2006). The findings of this study on the levels of VGLUT1-3 and VGAT 
in neostriatum, cortex and pons medulla compare well with the previous findings in 
cerebrum performed by our group (Bogen et al., 2006). This indicates that the decreases in 
the levels of specific synaptic vesicles is a general phenomena evenly distributed in 
forebrain, and not restricted to a specific brain region.  
 
GAD65, an isoform of the enzyme glutamate decarboxylase, was of interest in this study, 
being responsible for converting glutamate to GABA. No statistical difference in the 
amount of GAD65 per mg protein in synapsin I/II DKO mice was found, compared to WT 
mice. A ~22% decrease in the level of GAD65 in pons medulla almost reached statistical 
significance (p-value 0.052) and may be of biological relevance. The finding that GAD65 
is not reduced in the neostriatum, cortex and whole cerebrum of synapsin I/II DKO indicate 
that GABA synthesis in inhibitory synapses was not restrained by a reduced GAD65 
activity. (Benson et al., 1994) showed that GAD65 was positively immunostained in 
hippocampal neurons for synapsin I, suggesting that GAD65-positive varicosities that 
contact the somata and dendrites represent presynaptic specializations. The reason why the 
amount of GAD65 was not affected by the absence of synapsin I and II could be due to the 
fact that although GAD65 is found in membranes of synaptic vesicles, a pool of GAD65 is 
also found in the Golgi complex region of neurons, hereby “masking” an eventual loss of 
the enzyme in the vesicles (Kanaani et al., 1999). In addition the enzymatic activity of 
GAD65 may be altered, although the levels of proteins were not changed. 
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4.1.2 THE LEVELS OF CHOLINERGIC VESICLES IN PERIPHERAL NEURONS 
IN SYNAPSIN I/II DKO 
There are few publications on VAChT in the PNS. No significant decrease in the levels of 
VAChT was found in preparations of tounge or diaphragm from synapsin I/II DKO mice. 
However, none of the sample preparations obtained from tongue and diaphragm were 
suitable for detection of synaptophysin by Western blotting. It therefore appears possible 
that the amount of synaptic vesicles in preparations from skeletal muscle is insufficient to 
allow biochemical detection by immunoblotting. To address the question whether 
cholinergic vesicles in the peripheral nervous system co-localize with synapsins, methods 
such as confocal microscopy or electron microscopy could be employed. 
 
4.1.3 DIFFERENCE IN THE DEPENDENCE OF SYNAPSIN I AND II FOR 
SPECIFIC VESICULAR TRANSPORTERS 
The majority of vertebrate nerve terminals have been presumed to contain synapsin 
proteins (De Camilli et al., 1983; Sudhof, 2004; Walaas, Browning, and Greengard, 1988). 
Previous studies have reported major decreases in the number of synaptic vesicles in the 
reserve pool of synapsin deficient brains (Gitler et al., 2004; Li et al., 1995b; Rosahl et al., 
1995; Takei et al., 1995). The findings of Bogen et al. (2006) that VGLUT-3 and VMAT2 
in striatum and hippocampus do not co-localize with neither synapsin I nor II were 
therefore surprising. This study confirms the findings by Bogen et al. (2006), and further, 
have revealed another specific neurotransmitter transporter, VAChT, which is not present 
at reduced levels in forebrains of synapsin DKO mice. 
 
The molecular mechanisms responsible for the decreases in synaptic vesicles and vesicular 
transporters in the absence of synapsin I and II, remain unclear. The possibility that 
synapsin proteins could modulate the synthesis of vesicular transporters appears unlikely, 
since mRNA levels excluded a decreased expression of the genes encoding VGLUT-1 and 
VGLUT-2 (Bogen et al., 2006). Synaptic vesicles are covered with synapsins and could 
serve some role of vesicle stabilization. Lack of synapsins could therefore induce the 
vesicles to undergo spontaneous degradation. This was first suggested by Rosahl et al., 
(1995) saying that the decrease in synaptic vesicle proteins is due to a premature 
degradation in synapsin knockout mice. This degradation appears to occur in nerve 
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terminals as no increase in synaptic vesicle proteins could be detected in the cell bodies of 
the mutant mice (Rosahl et.al., 1995). 
 
The present data indicate that synaptic vesicles have a different vulnerability to 
degradation, based on their distinct relation to synapsin proteins. Anatomical studies, using 
confocal microscopy, indicated that VGLUT-1, VGLUT-2 and VGAT were co-localized 
with synapsins I and/or II in the areas studied (Bogen et al., 2006). In contrast, VGLUT-3 
and VMAT2, not decreased in mice lacking synapsin I and II, were not found to co-localize 
with synapsin I or II (Bogen et al., 2006). This indicates that VGLUT-3, VMAT2 and 
probably also VAChT, present in modulatory synapses, are present in synapsin I/II-
negative synaptic vesicles. These specific subgroups of vesicles were not decreased in the 
synapsin I/II double knockout. Confocal studies of VAChT and synapsin I and II must be 
performed to find out whether VAChT and synapsin I/II co-localize. 
 
We have studied the levels of VAChT in three different brain areas of synapsin DKO mice; 
the cholinergic long fibers in the cortex, interneurons in the neostriatum, and cholinergic 
terminals with origin in pons medulla. Our results indicate that the cholinergic interneurons 
in striatum, being decreased by 23% in synapsin DKO, are synapsin-dependent, while the 
cholinergic neurons in cortex and pons-medulla are not. Again, this can be approached by 
using e.g. confocal microscopy.  
 
In addition, we have studied the level of VAChT and synaptophysin in the PMS. There was 
no reduction in VAChT in the PMS in synapsin I/II DKO, which can indicate that these 
synaptic vesicles are synapsin I and II independent. 
 
4.1.3 PROTEINS IN WILD-TYPE MICE IN THREE BRAIN SECTIONS 
COMPARED TO CEREBRUM 
 
The levels of different vesicular proteins found in neostriatum, cortex and pons medulla in 
wild-type mice, were compared to the levels found in total forebrain. 
 
In our studies, the amount of VGLUT-1 was found to be slightly higher in cortex, 
compared to the level in whole cerebrum. The levels of VGLUT-1 in pons medulla were 
very low and not possible to quantify. Our findings correlate well with previous reports, 
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showing high levels of VGLUT-1 in the cortex (Fremeau et al., 2001; Varoqui et al., 
2002), most terminals in the synaptic fields in the dentate gyrus, hippocampus, striatum, 
and very low levels in the pons medulla (Bellocchio et al., 1998; Fremeau et al., 2001).  
 
VGLUT-2 is found in the pons medulla, brainstem, thalamus, striatum and hypothalamus, 
while lower levels are found  in the cortex and hippocampus (Fremeau et al., 2001; Herzog 
et al., 2001; Varoqui et al., 2002). In this study   45% higher and 23% lower levels of 
VGLUT-2 was seen in  pons medulla of wild type mice compared to cerebrum. 
 
VGLUT3 is expressed in much more restricted cell populations compared to VGLUT1 and 
VGLUT2 (Gras et al., 2002). An even more striking finding is that VGLUT3 is found in 
populations of non-glutamatergic cells, such as cholinergic interneurons in the striatum and 
nucleus accumbens, GABAergic interneurons in the cortex, hippocampus and 
interpeduncular nucleus, and in serotonergic neurons of the raphe nuclei (Fremeau et al., 
2002; Gras et al., 2002). The levels of VGLUT-3 were found to be 3-fold higher in the 
neostriatum compared to the level in total cerebrum.  
 
It has previously been reported that VGAT is evenly distributed in the brain (McIntire et 
al., 1997; Sagne et al., 1997), which was in accordance with our findings. Also GAD65, 
predominately present in membranes and GABAergic nerve endings (Kanaani et al., 1999; 
Soghomonian and Martin, 1998) was found at similar levels in all the brain areas studied. 
 
The level of VAChT was approximately two-fold in the neostriatum, and slightly lower in 
pons-medulla compared to the level in whole cerebrum. The level of synaptophysin was 
also lower in the pons medulla, possibly indicating a lower total number of nerve terminals 
and synaptic vesicles in this brain region. Litterature supporting these findings was not 
found.  
 
4.2 STUDIES ON THE DOPAMINERGIC SYSTEM IN AN ANIMAL 
        MODEL FOR ADHD 
 
Increasing evidence indicates that dysfunction of dopaminergic projections in the brain 
may be involved in major symptoms of ADHD (Davids et al., 2003; Oades et al., 2005; 
Russell, 2003; Sagvolden et al., 2005). Further support for this dopamine hypothesis has 
been provided by studies on the spontaneous hypertensive rat (SHR), the only animal 
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model that demonstrates the behavioural characteristics of ADHD, namely hyperactivity, 
impulsivity and problems with sustained attention (Sagvolden, 2000; Sagvolden et al., 
1992).  
 
4.2.1 THE D1-LIKE  RECEPTOR BINDING IN SHR COMPARED TO WKY 
A genetic association between ADHD and changes in the dopamine D1 - like receptor genes 
has been shown (Faraone and Khan, 2006; Faraone et al., 2005). Experiments have shown 
an impaired dopamine release in SHR (Russell et al., 1998), and the density of D1-like 
receptors might be changed as well  in the brain of SHR. However, it should be kept in 
mind that the SHR genotype is genetically complex, and there is no reason to expect that 
the phenotypical similarities between the human condition and the rat phenotype 
necessarily will be reflected in completely identical molecular changes.   
 
Conflicting data have been presented regarding dopamine receptor binding in the brain of 
SHR. In this study, employing binding analysis with the selective dopamine D1-like 
receptor antagonist  [3H]SCH23390 (Bourne, 2001; Hyttel, 1983) on membranes from 
cerebrum and neostriatum from 4 weeks old prehypertensive and 8 weeks old 
posthypertensive SHR rats, we  found that D1–like receptor binding was increased by 20 % 
in cerebrum of SHR, compared to control rats. This occurred both when using 0.5 nM [3H] 
SCH23390 and, with a slightly smaller effect, when using 1 nM of [3H] SCH23390 
although the latter did not reach statistical significance (p-value 0.061 by paired Student’s 
t-test). In contrast, the density of D1-like receptors was not altered in neostriatal membranes 
from SHR animals. These results may indicate a plausible up-regulation of D1/5-like 
receptors in widespread areas of the cerebrum, possibly as a consequence of reduced 
dopamine release in the SHR animals (Russell, 2003). 
 
These results are compatible with other studies. Due to the fact that the major part of brain 
dopamine is restricted to three systems in brain, i.e., the mesocortical, mesolimbic and 
nigrostriatal branches, previous reports on dopamine receptor binding in brain have 
investigated one or more of these systems. In a study by Carey et al. (1998), a higher 
density of D-1 like receptors was seen in the core and shell of the nucleus accumbens, and 
the olfactory tubercle. A down-regulation was found in the globus pallidus and septum. 
This is in accordance with findings by Kirouac & Ganguly, (1993), which showed 
increased density of D1-like receptor in nucleus accumbens, septal nuclei and globus 
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pallidus using receptor autoradiography. Preparations from SHR showed significantly 
higher binding of [3H] SCH23390 in nucleus accumbens and olfactory tubercle in a study 
reported by Kujirai et al. (1990). However, SHR was here compared to Sprague-Dawley 
rats, and whether the latter rat strain is an appropriate control strain for SHR is debatable 
(Linthorst et al., 1993).  
 
Other reports are more conflicting. While several reports show increases in density of D1-
like receptors in caudate putamen and nucleus accumbens in SHR, either using 
autoradiography (Carey et al., 1998; Kirouac and Ganguly, 1993; Kujirai et al., 1990; 
Watanabe et al., 1997) or striatal membrane preparations (Lim et al., 1989; Lim et al., 
1990), other studies report no difference (Linthorst et al., 1993; Watanabe et al., 1989).  
This discrepancy, with some studies showing no increase in striatum may be due to distinct 
methodological approaches being used. In addition, in the paper by Kujirai et al. (1990), 
Sprague Dawley rats were used as control rats, which may not be a proper control (see 
above). Moreover, genetic and functional heterogeneity may also be present in WKY 
animals from different suppliers (T. Sagvolden and Ø. Hvalby, personal communications).  
 
D1-like receptors have been reported to be functionally connected to working memory 
(Russell et al., 1998; Sagvolden et al., 2005). Working memory may have implications on 
delayed gradients and how reinforcers8 work. Shorter working memory, which may be 
caused by hypofunctioning of dopamine, means that the time window to associate 
behaviour with its consequences is shorter in ADHD. Reinforcers will then have low effect 
due to short time window. This can explain both the hyperactivity and impulsiveness, an 
explanation based on the dynamic developmental theory of ADHD, where each symptom 
can be explained through the effect of reinforcers (Sagvolden et al., 2005). 
 
4.2.2 CALCYON AND COMT 
Since dopaminergic systems have been hypothesized to be involved in the development of 
ADHD (Davids et al., 2003; Oades et al., 2005; Russell, 2003; Sagvolden et al., 2005), 
calcyon protein, a brain-specific D1-receptor-interacting protein involved in  the Ca2+ -
signaling of D1/D5, was examined in this study in both neostriatum and cerebrum of SHR. 
No difference in the amount of calcyon was found in SHR rats compared to WKY rats in 
neostriatum and cerebrum. This contrasts with preliminary findings of Sagvolden, Walaas, 
                                                 
8 Reinforcement associates behaviour and consequences 
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Middleton and Faraone (2006, in.prep.), where an increase in the level of mRNA encoding 
calcyon was seen. In a study by Laurin et al., (2005) the calcyon gene was implicated as a 
risk factor in the development of the ADHD. Although no change in the amount of calcyon 
protein was detected in neostriaum or in cerebrum in our study, one cannot exclude that 
calcyon is affected in ADHD. It is possible that Western blotting is insufficiently sensitive 
in order to detect small changes in proteins. A large number of replicates would then be 
needed in order to detect statistically significant changes. 
 
COMT (catecholamine O-methyltransferase) is an enzyme which catalyzes the degradation 
of catecholamines, including dopamine It was therefore of interest in this investigation to 
see whether the amount of COMT is changed in SHR compared to their WKY control rats. 
No significant difference was found in the amount of COMT proteins in SHR rats 
compared their control WKY rats in neostriatum and cerebrum. Although extensive 
research has been done concerning the genetics of COMT and ADHD, e.g. on association 
between Val158 Met polymorphism and ADHD, only limited research has been performed 
on protein levels of COMT in SHR,. The Val variant is associated with a higher activity of 
COMT and thermal stability, and has been convincingly implicated in a poor frontal lobe 
function across a number of cognitive tasks (Cheuk and Wong, 2006). However, meta 
analysis on studies between COMT polymorphisms and ADHD concluded that no 
significant association was present between the most commonT gene polymorphism and 
ADHD (Cheuk and Wong, 2006).  
 
4.2.3 NMDA-RECEPTORS 
Dopamine effects in brain are often mediated by modulation of major excitatory 
neurotransmission mechanisms, at either presynaptic or postsynaptic levels. Recent studies 
have shown an interaction between D1-receptors and the glutamate receptors designated 
NMDA-receptors in brain cells (Cepeda and Levine, 2006; Lee and Liu, 2004). This 
interaction between D1 and NMDA receptors has been proposed to involve activation of 
second-messenger signalling cascades after receptor stimulation. However, in recent years, 
another paradigm has emerged; involving the direct interaction between D1 and NMDA 
receptors. Since we found that the level of D1 receptors was shown to be increased in 
cerebrum of SHR, one might expect changes in the amount of NMDA-R subunits as well. 
However, no differences was found in the levels of NMDA-1 and NMDA-2A/B in SHR 
compared to control WKY rats, either in neostriatum or in cerebrum.  
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In contrast, preliminary findings by Sagvolden et .al., (2006, in prep.) on different levels of 
mRNA encoding these glutamate receptor subunits indicated possible differences, again 
emphasizing that levels and stability of mRNA may be under separate controls when 
compared to the steady state levels of the encoded proteins.  
 
Reports of activity-induced changes in the density of both D1/D5 and NMDA receptors 
have been presented (Cepeda and Levine, 2006; Lee and Liu, 2004). While NMDA 
receptor activity may recruit D1 receptors to the cell surface, the effect of D1 activation on 
NMDA receptors density is reported to be either decreased (Lee and Liu, 2004), or 
increased (Cepeda and Levine, 2006). This interaction can therefore have significant 
implications in  the generation of rational new treatments for psychiatric and neurological 
disorders, e.g. ADHD (Cepeda and Levine, 2006).  
 
4.3 CONCLUSION 
In the first part of this study, we focused on the three cholinergic centra in synapsin I/II 
DKO to see whether there is a change in VAChT in synapsin I/II DKO. In addition  
glutamatergic and gabaergic vesicular transporters were examined in the same brain areas 
of synapsin I/II DKO. Our results showed a decrease of VAChT in neostriatum, indicating 
that synapsin I/II is of importance for the cholinergic interneurones found in neostriatum, in 
contrast to the other cholinergic centra examined. In addition, the reduction in VGLUT-1-2 
an VGAT, and no change in VGLUT-3 in three brain areas of synapsin I/II DKO  gave 
support to previous findings by our group, saying that some synaptic vesicles are synapsin 
dependent, while others are not. To further evaluate whether cholinergic centra are 
synapsin I and/or II dependent, methods like confocal microscopy and electron microscopy 
may be used to assess this question 
 
In the second part of this study we found an increase in the brain density of D1-like 
receptors in the SHR,  an animal model of ADHD, This increase might be related to the 
proposed hypofunctioning of dopamine in SHR, and may thus indirectly support the 
hypothesis of dopaminergic system dysregulation in ADHD.  Otherwise, no changes were 
detected in the SHR when examining the protein levels of the dopaminergic markers 
calcyon and COMT, and the glutamate receptor form NMDA-R.   
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Hence, these data give only preliminary support to a possible link between dopaminergic 
hypofunction and ADHD aetiology.  
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APPENDIX 
I. CHEMICALS AND REAGENTS 
Chemical/Reagent Abbreviation Manifacturer Cat.no 
 [N-methyl-3H]SCH 23390 [3H]SCH 23390 Amersham 
Biosciences 
TRK876-100UCI 
DL-Dithiothreitol DTT Sigma Aldrich D0632 
30% Acrylamide/ Bis solution, 
37.5:1 
Polyacrylamide Bio-Rad Laboratories 161-0158 
Amersham ECL plus TM Western 
Blotting detection reagent 
ECL-plus GE Healthcare RPN2132 
Ammonium persulfate  Sigma Aldrich A-9164 
BCA Protein Assay Kit  Pierce 23225 
Bromophenol Blue BPB Sigma Aldrich B5525 
dH20  - - 
Glycerol  Chemi-teknik  
Glycine  Sigma Aldrich G7126 
HRP-labelled anti-goat secondary 
antibody 
 Santa Cruz 
Biotechnology 
Sc-2438 
HRP-labelled anti-mouse 
secondary antibody 
 GE-Healthcare NA 931 
HRP-labelled anti-rabbit secondary 
antibody 
 GE-Healthcare NA 934 
Hydrochloric acid,  fuming 37% HCl Sigma Aldrich 84426 
Ketanserine tartrate  Tocris Bioscience 0908 
Methanol  VWR 20 903.368 
N,N,N′,N′-
Tetramethylethylenediamine 
TEMED Sigma Aldrich T22500 
Polyethylenimine  Sigma Aldrich 468533 
Ponceau S    
Potassium chloride KCL Merck 1.04936.1000 
 
Powdered skimmed milk 
 
 Nestle´  
Precision Plus Protein Dual Color 
Standards 
Protein Standard Bio-Rad Laboratories 161-0374 
Primary antibodies against  Synaptic Systems vGLUT-2-135402 
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vGLUT-2 (rabbit polyclonal) 
 vGLUT-3 (rabbit polyclonal), 
vACTH ( rabbit polyclonal), 
NMDA-1 (mouse monoclonal) 
vGAT (mouse monoclona) 
(SYSY) vGLUT-3-135203 
vACTH- 139103 
NMDA-1-114001 
vGAT- 131 011 
Primary antibodies against  
COMT (mouse polyclonal), 
GAD65(mouse polyclonal) 
 
 BD Transduction 
Laboratories 
COMT- 611970 
GAD65- 559931 
Primary antibody against  
Calcyon (goat polyclonal) 
 Santa Cruz 
Biotechnology 
Sc-10837 
Primary antibody against  
vGLUT-1 
 Made in 
oulaboratorie as 
described by Bogen 
et.al., 2006 
 
Primary antibody against 
synaptofysin 
 Sigma Aldrich S5768 
SCH23390 hydrochloride SCH23390. HCl Tocris Bioscience 0925 
Sodium chloride NaCl Sigma Aldrich S9625 
Sodium dodecyl sulphate SDS Sigma Aldrich L-3771 
Sucrose  Sigma Aldrich S0389 
Tris (hydroxymethyl) Tris Sigma Aldrich T-1378 
Tween-20  Sigma Aldrich P1379 
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II. CONTENT OF BUFFERS AND SOLUTIONS  
a)  BUFFERS AND SOLUTIONS FOR WESTERN BLOTTING 
 
      
Reagents Ingredients Amount 
    
  
  
  
Solution A Tris-HCl (pH 8,8)                           45,5 g 
  SDS                     1,0 g 
  dH20                                 ad 250 ml   
      
      
Solution E Tris-HCl (pH 6,8) 
                                   
15,1 g 
  SDS 1,0 g 
  dH20                                 ad 250 ml 
      
4 x sample 
buffer DTT                                                              0,308 g 
  Tris   0,121  g 
  Bromophenol blue  0,050  g 
  20 % SDS    2,0    ml 
  87% Glycerol   2,3    ml 
  dH20    0,221 ml 
      
      
Running 
buffer  (10 X) Glycine  144,0 g 
  Tris  30,3 g 
  SDS  10,0 g 
  dH20    ad 1,0   L 
  
(Running buffer 1X:  500 ml running buffer 
(10X) + 4,5 L dH20   
      
      
Towbin (10 X) Tris   30,3 g 
  Glycine  144,0 g 
  dH20    ad   1 L 
  
(Towbin 1 X: 500ml of Towbin 10x + 1000ml 
methanol+3,5L dH20) 
  
 
      
50 mM Tris-
HCl buffer  Tris   12,1 g 
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( pH 7,4) dH20 ad  2,0 L 
     
  
Dissolve in 1,8L of dH20, adjust to desired pH 
with    
  concentrated HCl and add dH20 to 2L.   
Blocking 
buffer (5%) Powdered skimmed milk                            2,5 g 
  5 % Azid (NaN3 )  100 µl 
  TBS-Tween   ad    50 ml 
Ponceau S Ponceau   2 g 
  Acetic acid (100%)                                               30 ml 
  dH20                                                                     ad 1 L 
      
      
ECL-plus Assuming 1 nitrocellulose filter:   
  Solution A   2 ml 
  Solution B      50µl 
      
 
b) BUFFERS AND SOLUTIONS FOR RECEPTOR BINDING ASSAY  
 
Reagents Ingredients Amount 
      
50 mM Tris-HCl 
buffer  Tris   12,1 g 
( pH 7,4) dH20 ad  2,0 L 
     
  
Dissolve in 1,8L of dH20, adjust to desired pH 
with    
  concentrated HCl and add dH20 to 2L.   
     
50mM Tris-HCL     
incubation buffer Tris                             12,1 g 
(pH 7.4) NaCl                             14,0 g 
  KCl                             0,75 g 
  CaCl2                                          0,59 g 
  Mg Cl2                                          0,19g 
  dH20                                        ad 2 L 
     
     
     
  
Dissolve in 1,8L of dH20, adjust to desired pH 
with.   
   concentrated HCl and add dH20 to 2L   
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c) SOLUTIONS FOR PREPARATION OF DIAPHRAGM AND TONGUE  
 
Reagents Ingredients Amount 
   
1M KCl KCl 3,78 g 
 dH20   ad  50 ml 
     
     
10 % TCA/acetone TCA 1 ml 
 Acetone 9ml 
   
   
Urea Sample buffer Tris/glycine (10X stock), pH 8.6 1ml 
 DTT 15,4 mg 
 Urea 4,8 mg 
 dH20   Ad 10 mL 
   
 
(Tris/glycine (10 % stock) made of 2,4 g Tris+ 
1,6g glycine in 100 ml dH20 . Adjusted to 
desired pH with concentrated HCl  
   
Acetone/DTT/NaF DTT 77,1 mg 
 NaF 42 mg 
 Acetone Ad 50 ml 
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.  
